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ABSTRACT

NOVEL INSIGHT INTO THE LIVER-LUNG AXIS IN ALCOHOL-ENHANCED
ACUTE LUNG INJURY

Lauren G. Poole
June 8, 2017

Background. Individuals who chronically abuse alcohol are almost 4 times more
likely to develop Acute Respiratory Distress Syndrome (ARDS), the most severe
form of Acute Lung Injury (ALI), but the mechanisms by which alcohol abuse
sensitizes the lung to injury are poorly understood. However, the lung appears to
share many parallel mechanisms of injury with the liver- a primary target of alcohol
abuse. The overarching goal of this dissertation was therefore to expand on
established mechanisms of alcohol-induced liver injury to ask innovative questions
about mechanisms of alcohol-enhanced acute lung injury, as well as to develop new
tools that may be used to gain novel insight into the liver-lung axis of alcoholinduced injury. Methods. Male mice were exposed to ethanol containing liquid diet
either chronically (6 weeks) or in a chronic + binge pattern. Some mice were
administered lipopolysaccharide (LPS) to induce acute lung injury. Lung injury and
inflammation were assessed. To develop an animal model by which liver-lung
interactions could be investigated, tamoxifen-loaded polymer nanoparticles were
administered intrasplenically to a tamoxifen-inducible, Cre-mediated, dualvi

fluorescent reporter construct. Results. Chapter III of this dissertation describes a
mechanism by which plasminogen activator inhibitor-1 (PAI-1) is involved in alcoholenhanced acute lung injury. Specifically, it was proposed that PAI-1-mediated fibrin
accumulation promotes the aggregation of platelets, thereby propagating lung injury
and inflammation. Chapter IV of this dissertation characterizes a recently-developed
animal model of chronic + binge alcohol exposure, finding that animals exposed to
chronic + binge alcohol exposure exhibit pulmonary inflammation and airway
hyperresponsiveness. Finally, Chapter V of this dissertation develops an animal
model to investigate liver-lung interactions during chronic alcohol exposure. It was
found that tamoxifen-loaded polymer nanoparticles, when administered
intrasplenically, selectively alter the genetics of hepatic cells, while avoiding other
tissues, including the lung. Discussion. The work presented in this dissertation has,
in conclusion, uncovered novel mechanisms by which alcohol sensitizes the lung to
a second injury, shown that ethanol alone is sufficient to cause lung inflammation,
and developed a novel animal method to examine liver-lung interactions during
alcohol exposure.
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CHAPTER I

INTRODUCTION1

A.

Background and rationale for this study

1. Alcohol use and its impact
The discovery of fermented beverages was likely accidental and derived
from improper food storage. As agrarian culture developed throughout the world,
so did the intentional cultivation of crops for alcoholic beverage production.
Alcoholic beverages were valued in ancient cultures for several reasons beyond
them being a ‘social lubricant’ (1). In a time when potable water was difficult to
acquire, alcohol acted as a relatively safe source of hydration. Additionally,
alcohol’s modest nutritional value supplemented malnourishment. Furthermore,
alcohol had significant medicinal value as an antimicrobial agent. Taken
together, the pervasive nature of alcohol consumption throughout the world is
unsurprising. Even in cultures that forbid alcohol consumption, the development
of such taboos speaks to the fact that these peoples have been exposed to
alcohol consumption.
There are many potential benefits of alcohol consumption, as discussed
above. Despite these benefits, the idea of a need for moderation in alcohol
consumption is as ubiquitous as the consumption of alcohol itself; indeed, almost
1
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every culture frowns upon public intoxication and alcohol abuse and/or
dependence. For example, Aristotle strongly extols the virtue of temperance in
his work, “The Nicomachean Ethics.” In modern society, alcohol abuse has an
even more significant impact. For example, there is, on average, more than one
alcohol-related driving fatality every hour in the US (2).
In addition to these social consequences, alcohol abuse significantly
impacts health. Alcohol requires relatively high concentrations to exert many of
its toxic effects in organisms and is therefore, arguably, not an incredibly potent
toxin. However, alcohol must be consumed in relatively high doses to cause any
noticeable inebriating effects; the legal driving blood alcohol content (BAC) in
most US States (0.08% w/v) translates to ~20 mM ethanol. Therefore, the sheer
volume of alcohol which humans consume is enough to offset its low potency. In
fact, one could argue that alcohol is the most common poison voluntarily
consumed at toxic doses by the human population. In the United States alone,
over 17 million adults suffer from an alcohol use disorder (AUD), a condition that
the National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines as “a
chronic relapsing brain disease characterized by compulsive alcohol use, loss of
control over alcohol intake, and a negative emotional state when not using.”
Chronic alcohol consumption/abuse has been demonstrated to directly damage
several organs, including liver (3), lung (4), skeletal muscle and heart (5), the
brain (6), and the pancreas (7). Additionally, alcohol consumption increases the
risk of developing several cancers; it is considered a group 1 carcinogen for
cancers of the GI tract, liver, breast and pancreas by the International Agency for
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Research on Cancer (8). Ultimately, alcohol consumption is responsible for ~6%
of all disability-adjusted life years (DALY) lost in the United States (9), most of
which are attributable to alcohol-induced toxicity as opposed to alcohol-related
accidents.

2. Alcoholic Liver Disease
The liver is located between the intestinal tract and the rest of the body,
making it a critical organ in the clearance of toxins and xenobiotics, including
alcohol, that enter the portal blood. The concentration of alcohol found in the
portal blood is much higher than those in the systemic circulation. Additionally,
the liver is the primary site of alcohol metabolism, which produces many toxic
metabolites. Therefore, it is unsurprising that the liver is a primary target of
alcohol toxicity. Although excessive alcohol consumption has been associated
with organ toxicity since ancient times, the first suggestion that alcohol
consumption may directly cause organ damage is credited to Thomas Addison in
1836 (10).
Alcoholic Liver Disease (ALD) affects millions of patients worldwide each
year. The progression of ALD is well-characterized and is actually a spectrum of
liver diseases, ranging initially from simple steatosis, or fat accumulation, to
inflammation and necrosis (often called steatohepatitis), and ultimately, to fibrosis
and cirrhosis. Although the risk of developing ALD increases in a dose- and
time-dependent manner with alcohol consumption (11, 12), only a small fraction
of even the heaviest drinkers develop the severe form of the disease, suggesting

3

that other environmental (e.g., hepatitis B virus (HBV) or hepatitis C virus (HCV)
infection) or genetic (e.g., gender or polymorphisms in key genes) factors
contribute to overall risk (13). Clinical management of ALD primarily focuses on
maintaining abstinence in the alcoholic, and on treating sequelae associated with
acute alcoholic hepatitis or cirrhosis (14). The effects of decompensation (e.g.,
hepatorenal syndrome) usually lead to the death of the patient, except in the
case of a successful liver transplant (15). Furthermore, the overall risk of
developing hepatocellular carcinoma (HCC) increases roughly 20-fold by
preexisting cirrhosis, even in patients in which compensation is maintained (i.e.,
‘stable cirrhotics’) (16). HCC has an even more dismal prognosis than cirrhosis
with very high mortality rates (17).

3. Alcoholic lung phenotype
The lung is also recognized as a target of chronic alcohol abuse, and
alcohol-related lung injury is estimated to account for tens of thousands of deaths
in the United States each year (18). Although chronic alcohol consumption is not
directly linked to the development of an “alcoholic lung disease” (i.e., as it is to
liver disease), alcohol is a significant risk factor in the morbidity/mortality of lung
damage from other causes. For example, acute respiratory distress syndrome
(ARDS), the most severe form of acute lung injury (ALI), occurs 3.7 times more
often in individuals meeting the diagnostic criteria for alcohol use disorders (19,
20). Furthermore, Moss and colleagues demonstrated that chronic alcoholics
who developed ARDS showed in-hospital mortality rates of 65%, whereas
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nonalcoholic patients had mortality rates of 36% (19-21). The exact mechanisms
by which alcohol mediates these effects on the lung are unknown, but
experimental ethanol exposure has been associated with the up-regulation of
pro-inflammatory cytokines (22-24), disruption of regulatory signaling pathways
(25), activation of tissue remodeling (26, 27), and the induction of oxidative stress
in rodent lungs (28). All of these factors may promote the development of the
“alcoholic lung” phenotype. This phenotype appears to enhance the host’s
susceptibility to serious lung diseases, including ARDS, ALI following severe
trauma (e.g. car accident, gun shot, etc.), and respiratory infection (e.g.,
pneumonia) (18). In fact, having an alcoholic use disorder is a major
independent risk factor for development and susceptibility to sepsis-induced
ARDS, even after adjusting for smoking status and co-morbitities (21).
To investigate mechanisms by which alcohol exposure sensitizes the lung
to sepsis-induced ARDS, experimental mouse models may be utilized.
Intraperitoneal (i.p.) injection of bacterial lipopolysaccharide (LPS), or
endotoxemia-induced lung injury, is one such animal model employed to study
ALI and ARDS (29, 30). Indeed, this model has been demonstrated to cause
sequestration of neutrophils in the pulmonary vasculature and interstitium (31,
32). Furthermore, i.p. LPS administration has been demonstrated to cause
pulmonary edema, diffuse alveolar damage, and induction of inflammatory
cytokines and chemokines, such as IL-6 and MCP-1 (33). Systemic
administration of LPS (versus intratracheal) is a particularly relevant model to
investigate mechanisms of alcohol-induced organ pathology, as chronic alcohol

5

consumption has been demonstrated to increase systemic LPS in patients (34).
Systemic endotoxin may, in turn, damage the lung directly or via inflammatory
mediators released from other tissues. Furthermore, although intratracheal
administration of LPS has been demonstrated to cause a large influx of PMNs
into the alveoli, there are concerns that this model may include confounding
factors, such as aspiration injury (32). In the setting of chronic alcohol exposure,
ethanol feeding enhances glutathione depletion and oxidative stress in a rat
model of endotoxemia-induced ALI (4, 28). Additionally, this group recently
characterized the effects of chronic ethanol pre-exposure on endotoxemiainduced ALI (35). Therefore, experimental endotoxemia with chronic ethanol preexposure is a useful experimental model to investigate mechanisms by which
alcohol increases risk and susceptibility to ARDS. Although this experimental
mouse model has been characterized, mechanisms by which ethanol preexposure exacerbates endotoxemia-induced ALI remain poorly understood. It is
proposed that building on knowledge of established mechanisms of alcoholinduced injury in the liver- a direct target organ of alcohol toxicity- may aid in
exploration of mechanisms of alcohol-enhanced ALI.

4. Parallel mechanisms of injury in the liver and lung
A major focus of the Arteel group’s recent research has been to
investigate liver-lung interactions in the setting of chronic alcohol abuse, and this
group has accordingly sought to develop and characterize animal models to
study both systems simultaneously. Indeed, the liver and lung share many

6

mechanisms of injury. First, resident macrophages, e.g., Kupffer cells in the liver
and alveolar macrophages in the lung, play key roles in mediating the
inflammatory response via the release of inflammatory cytokines. Alcoholinduced damage to both organs also appears to involve oxidative stress (4, 36).
Furthermore, alcohol appears to enhance damage caused by a second “hit,” or
inflammatory stimulus in both organs (37-40). For example, damage caused by
intraperitoneal injection of LPS is enhanced by alcohol consumption in both the
liver and the lung, as discussed briefly in Section 3 of this Chapter (28, 41, 42).
Finally, an altered extracellular matrix (ECM) profile appears to be a key feature
of pre-fibrotic inflammatory injury in both tissues. This pre-fibrotic, inflammatory
remodeling of the ECM which does not alter the overall structure of the organ is a
concept known as “transitional ECM remodeling” (43, 44). This group has
demonstrated that the hepatic ECM responds dynamically to alcohol exposure,
sensitizing the liver to LPS-induced inflammatory damage (38). Similarly, data
from the laboratory of Jesse Roman, has demonstrated that chronic alcohol
exposure alters the expression and degradation of the ECM, favoring fibronectin
deposition (40). Although alcohol-induced liver and lung injury are by no means
synonymous, they share many mechanisms of alcohol-induced organ injury, and
understanding of one system can be used to leverage novel questions in the
other.

7

5. Coagulation and fibrin ECM remodeling in alcohol-induced organ
injury
A predominant theme of this dissertation is to explore a potential role of
established mechanisms of alcohol-induced liver injury in the setting of alcoholenhanced ALI. As discussed in Section 4 of the current Chapter, one potential
parallel mechanism of liver and lung injury in response to alcohol is the
development of a transitional ECM. To re-iterate, the “transitional ECM” can be
defined as alterations in the amount or composition of the ECM that occur in the
inflammatory, pre-fibrotic stages of disease that do not alter the overall structure
or function of the organ (44). Fibrin(ogen) is one such transitional ECM protein in
particular that is known to be affected by exposure to alcohol. Plasminogen
activator inhibitor-1, or PAI-1, is a key regulator of fibrin degradation (i.e.,
fibrinolysis). PAI-1 is an acute phase protein normally expressed by adipocytes
and endothelial cells, but is also expressed by other cells, including
macrophages, during times of inflammation and/or stress (45). Classically, PAI-1
is an inhibitor of tissue-type plasminogen activator and urokinase-type
plasminogen activator (tPA and uPA, respectively), thereby preventing the
conversion of plasminogen to plasmin. Plasmin is a protease which degrades
insoluble fibrin to fibrin degradation products. Thus, PAI-1 induction negatively
regulates fibrinolysis.
The Arteel group has identified the critical role of PAI-1 in the progression
of alcohol-induced liver injury. Specifically, knocking out PAI-1 produced potent
anti-inflammatory effects in a chronic enteral alcohol model (46). Additionally,
data from the Arteel group has also revealed a key role for PAI-1 in acute
8

alcohol-induced liver injury (38). In this setting, acute ethanol pre-exposure
enhanced LPS-induced fibrin deposition in the hepatic sinusoidal space, and
inhibiting fibrin deposition protected against enhanced liver injury and
inflammation. Similar effects have also been demonstrated in other models of
hepatic inflammation, including LPS-induced liver injury enhanced by partial
hepatectomy (47). PAI-1 is also known to contribute to the development of ALI
and ARDS (48, 49), and elevated plasma PAI-1 levels in patients with these
conditions is associated with increased mortality (50-52). PAI-1 induction has
also enhances susceptibility to LPS-induced ALI (53). PAI-1 induction also
exacerbated fibrosis in a model of experimental, bleomycin-induced pulmonary
fibrosis (54). Although the role of PAI-1 has been studied in many models of lung
injury, including cancer (55), fibrosis (56), and ALI (57), the role of PAI-1 in
alcohol-enhanced ALI remains largely unknown.
PAI-1 also indirectly regulates the expression of many other ECM
proteins, including laminin, proteoglycan, and type IV collagen via inhibition of
matrix metalloproteinases (MMPs) (58-61) (62). PAI-1 induction has also been
shown to enhance fibronectin ECM deposition (63). Many cell types, including
alveolar macrophages, bind to select ECM proteins under basal conditions, and
cell surface receptors known as integrins mediate crosstalk between the ECM
and the cell (64). For example, fibrin interacts with RGD-binding integrins,
including integrin αVβ3. The Arteel group has demonstrated that blocking fibrinintegrin interactions protects against alcohol-induced liver injury with no effect on
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fibrin accumulation (65), suggesting that this integrin signaling is critical for the
progression of liver injury.
Altered integrin signaling may also contribute to injury in the lung. Alveolar
macrophages, for example bind with high affinity to fibronectin via the integrins
α5β1. Chronic alcohol exposure has been shown to cause deposition of a
fibronectin-enriched pulmonary ECM. Data from the Roman group has
demonstrated that monocytes cultured on ECM from ethanol-exposed alveolar
type II cells have an enhanced pro-inflammatory phenotype, and that blocking
integrin α5β1-mediated monocytye-fibronectin interactions attenuates this proinflammatory phenotype (62). Ligation of integrin αVβ3, an integrin receptor for
fibrinogen, vitronectin, and other ECM proteins that may be altered by alcohol
has also been shown to be pro-inflammatory (66). PAI-1 may alter integrin
signaling, both by promoting accumulation of integrin ligands, such as
fibrin(ogen), as well as more directly inhibiting ECM-integrin interactions. For
example, PAI-1 induction can inhibit vitronectin-integrin interactions, impairing
tissue repair (67). Taken together, these data suggest that changing the ECM
substratum can alter integrin signaling, and subsequently may promote
inflammation and injury in a tissue. This dissertation will explore the hypothesis
that PAI-1-mediated transitional remodeling of the pulmonary ECM, specifically
accumulation of fibrin, may contribute to alcohol-enhanced acute lung injury,
potentially via altered ECM-integrin signaling.
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6. Murine models of alcohol exposure
At this point, it becomes necessary to explore the strengths and limitations
of experimental models that may be used to investigate the questions presented
in this dissertation. Murine models of alcohol exposure are one of the most
valuable tools available to study the toxic effects of alcohol exposure, due to their
relatively low maintenance cost and the wide prevalence of genetically modified
strains available. Many potential routes of alcohol exposure are available in
rodent models, including intravenous or intraperitoneal administration, as well as
inhalation. While these models may be useful for investigating other pathologies
associated with alcohol abuse, such as addiction, they produce little to no
relevant alcohol-associated pathology, such as liver injury, in mice (68).
Moreover, alcohol exposure in humans is overwhelmingly via an oral route.
Therefore, oral administration of alcohol to mice is most commonly utilized to
investigate alcohol-induced organ toxicity.
Murine models of oral alcohol exposure address different patterns of
alcohol abuse, including acute (binge) drinking, as well as chronic abuse. Acute
alcohol exposure models typically involve administration of ethanol (4-6 g/kg) via
oral gavage over the course of 1-3 days. Pathologic changes (e.g., hepatic lipid
accumulation and inflammatory cell recruitment) in acute ethanol models are
typically minimal, yet these models can be useful for detecting biochemical (e.g.,
alterations in lipid/glucose metabolism) caused by alcohol (69). Furthermore,
acute alcohol exposure, at doses that are not overtly toxic themselves, enhances
the toxicity of other compounds, such as xenobiotics or bacterial endotoxins
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(e.g., LPS). For example, in the liver, acute alcohol administration exacerbates
damage caused by LPS (41). In the lung, acute alcohol exposure has been
shown to exacerbate pulmonary congestion and inflammation in a model of burn
injury (70).
Chronic administration of ethanol to mice is typically achieved by ad
libitum feeding, either by ethanol in drinking water or a “forced choice” model of
alcohol exposure, in which alcohol is incorporated into a liquid diet that serves as
the only source of calories. In the lung, chronic administration of ethanol in
drinking water (20% vol/vol for two weeks) depletes pulmonary glutathione levels
and causes dysfunction of alveolar macrophages in mice (71). However, there
are several concerns with utilization of this “ethanol in drinking water” mouse
model, including low blood alcohol content (BAC), dehydration, and lack of an
appropriate nutritional control (72). Furthermore, this model lacks significant
manifestation of pathology in target organs, such as the liver. Indeed, Best et al.
observed in 1949 that there was “no more evidence of a specific toxic effect of
pure ethyl alcohol upon liver cells than there is for one due to sugar” (73). Based
on these observations, it was proposed at the time that ALD was due to
nutritional deficiencies rather than to alcohol itself.
To address these concerns, Lieber and DeCarli developed the first
“forced-choice” model of chronic alcohol exposure, in which rats were
administered a nutritionally complete ethanol-containing or iso-caloric maltose
dextran-containing liquid diet for six weeks, with alcohol added in increasing
concentrations up to 36% total calories (74). This feeding model at least partially
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overcomes the rodent’s natural aversion of alcohol, and thereby achieves higher
BACs (typically around 0.10 g/dL) (75). Use of this model solidified the
hypothesis that alcohol is indeed a direct hepatotoxin. In rats and mice, the
Lieber-DeCarli liquid diet produces hepatic steatosis, mild elevations in plasma
transaminases, and some necroinflammatory changes in the liver. In the lung,
chronic alcohol exposure via ethanol containing liquid diet depletes glutathione
levels (76), causes remodeling of the ECM (62), causes mitochondrial
dysfunction (77), and sensitizes the lung to endotoxemia-induced ALI (35).
Although these mechanisms of injury are important for understanding how
chronic alcohol abuse sensitizes the lung to a second injury, this model does not
produce overt histologic injury or inflammation in the lung.
A more robust model of chronic alcohol exposure involves enteral
administration of ethanol-containing liquid diet via surgical implantation of an
intragastric pump. In rodents, this feeding model produces micro- and macrovesicular steatosis, apoptosis, inflammatory cell infiltration, and focal necrosis,
making this model one of the most relevant for producing pathologies associated
with ALD in humans (78). This model also produces ethanol-mediated toxicity in
other organs, such as the pancreas (79). The effects of enteral alcohol exposure
on other target organs, including the lung, is unknown. However, the technical
skill required for the surgical implantation of the pump used in this model limits its
widespread implementation.
Recently, the laboratory of Dr. Bin Gao developed the chronic + binge
mouse model of alcohol exposure (80). In this model, mice are acclimatized to
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control (0% ethanol) Lieber-DeCarli liquid diet for 5 days, followed by 10 days of
5% (v/v) ethanol-containing or iso-caloric control liquid diet. Then, animals
receive a single binge (5 g/kg) of ethanol. This model more accurately
reproduces drinking patterns of alcoholic patients who typically have a history of
chronic drinking coupled with episodes of binge drinking. In animals, this alcohol
exposure model produces high BACs (approximately 0.4 g/dL), elevations of
plasma transaminases, and steatohepatitis which is predominately neutrophilic in
nature, similar to what is observed in patients with alcoholic hepatitis.
Furthermore, this model requires only moderate technical skill, and is relatively
low-cost. Overall, this mouse model reproduces pathologies seen in human
alcoholic patients and is relatively simple to perform, making it a useful
experimental model for addressing questions relating to alcohol toxicity in target
organs. However, the effects chronic + binge alcohol exposure on target organs
other than the liver, such as the lung, have not been characterized.

7. Organ-organ crosstalk during alcohol exposure
As discussed throughout the current Chapter, alcohol abuse affects
several organs and cell types in the body. For example, end-stage,
decompensated liver disease is widely recognized as a systemic disorder. In
fact, in patients with end-stage liver disease, cause of death is usually due to
multiple organ failure, rather than liver disease itself (81). In one recent study of
patients with alcoholic hepatitis (AH), 36% of patients developed multiple organ
failure (82). In addition to the liver, kidney failure was found to be the most
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common, followed by circulatory failure, coagulopathy, respiratory failure, and
neurological failure. Ultimately, 90-day mortality in patients with multiple organ
failure was found to be significantly higher than those without. Furthermore,
patients with AH are also susceptible to the development of systemic
inflammatory response syndrome (SIRS). This condition has also been
associated with increased mortality. Indeed, multiple organ failure and
widespread, systemic inflammation, is a hallmark of the end stage of alcoholic
liver disease.
In addition to the end stage of disease, communication between the liver
and other organs may be involved in the progression of disease in earlier, (i.e.,
inflammatory) stages. A primary goal of this dissertation is to investigate organorgan interactions in the setting of chronic alcohol abuse, specifically,
interactions between the liver and lung. The idea of the liver-lung axis in the
setting of chronic alcohol exposure is based on clinical data demonstrating that
patients with a diagnosed alcohol use disorder have increased incidence of and
mortality from acute respiratory distress syndrome (ARDS), and in ARDS
patients with hepatic failure, mortality increases to almost 100% (83). More
recent data have indicated that even early liver dysfunction in ARDS is
associated with worse prognosis in these patients (84). Additionally,
experimental data suggest that communication with the liver may be required for
lung injury in ALI models. For example, pulmonary injury induced by LPS can be
altered by mediators released from the liver (e.g., TNFα). Indeed, in an elegant
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study by Siore and colleagues, LPS-induced lung damage required perfusion
through the liver (85).
In a more recent study from the Arteel group, mice were exposed to
chronic ethanol on the Lieber DeCarli liquid diet for six weeks, followed by
intraperitoneal injection of LPS to produce endotoxemia-induced ALI (35). The
differential effects on cytokine expression in systemic circulation and locally in
the lung (i.e., in the BALF) were examined. Animals pre-exposed to ethanol diet
had significantly elevated levels of plasma TNFα after LPS injection compared to
animals fed a control diet. TNFα levels in the BALF, however, were unaffected,
yet ethanol pre-exposed animals had elevated levels of the TNFα-responsive
chemokines, MIP-2 and KC. This elevated chemokine expression also
correlated with increased pulmonary neutrophil recruitment. Interestingly,
blocking systemic TNFα using a TNFα-inhibiting antibody, etanercept,
significantly attenuated the alcohol-enhanced pulmonary chemokine expression,
and ultimately, alcohol-enhanced lung injury and inflammation after LPS. While
the liver is not the sole source of systemic TNFα in this experimental setting,
other studies have demonstrated that ablation of Kupffer cells shows that these
cells are in fact a predominate source of plasma TNFα in experimental
endotoxemia (86). These data, however, merely suggest a liver-lung axis in this
disease state. Targeted animal models to specifically investigate the role of liverderived mediators are not yet available. Therefore, a major goal of this
dissertation is to develop a more specific system to directly examine the role of
hepatic-derived cytokines in alcohol-enhanced pulmonary injury.
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8. Statement of goals
As discussed throughout this chapter (Section 4), the liver and the lung
share many parallel mechanisms of injury in response to alcohol exposure, such
as transitional remodeling of the ECM. Furthermore, as discussed in Section 7,
the liver and lung may communicate during the development of disease.
Therefore, the goal of this dissertation is to expand on established mechanisms
of alcohol-induced liver injury to ask innovative questions about mechanisms of
alcohol-enhanced acute lung injury, as well as to develop new tools that may be
used to gain novel insight into the liver-lung axis of alcohol-induced injury. These
goals will be discussed in detail in the following Section.

B.

Aims and proposals

1. Investigating the role of PAI-1 in alcohol-enhanced acute lung injury:
parallel mechanisms of liver and lung injury

This dissertation proposes that exploring parallel mechanisms of liver and
lung injury in response to chronic alcohol exposure will enhance the field’s
understanding of alcohol-induced organ injury as a whole, as well as provide new
targets for therapy. Recent work in the Arteel laboratory indicates that activation
of plasminogen activator inhibitor-1 (PAI-1) and subsequent fibrin ECM
remodeling drives inflammatory liver damage in alcohol-induced liver injury.
Previous studies have established that PAI-1-mediated ECM remodeling
contributes to inflammatory damage in several organs, including lung. However,
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the role of PAI-1 in alcohol-enhanced ALI remains unknown. It is hypothesized
that PAI-1 induction and PAI-1-mediated fibrin accumulation in the lung is critical
for the progression of alcohol-related lung inflammation. The goals of the first
Aim of this dissertation are therefore 1) to establish if PAI-1, as well as
downstream targets of PAI-1 (e.g., fibrin) are up-regulated in a two-hit mouse
model of chronic alcohol exposure and experimental endotoxemia, 2) to
determine the role of PAI-1 in injury and inflammation in this model using PAI-1
knockout mice, and 3) to establish a potential mechanism by which PAI-1 and
fibrin are involved in alcohol-enhanced ALI.

2. Characterizing lung injury in a clinically relevant mouse model of
“chronic + binge” alcohol exposure

A major focus of research in the Arteel group is to understand how alcohol
abuse affects the organism as a whole, including multiple target organs
simultaneously. One common limitation of the models typically employed to study
the effects of alcohol on the lung is the absence of relevant pathology in other
target organs, such as the liver. Indeed, the ethanol in drinking water model,
which is commonly used to study alcohol-induced lung toxicity, has been
demonstrated to cause little to no liver pathology. Interestingly, only a small
minority of patients with alcohol use disorders have histologically normal livers
(87). Established in 2013, the “chronic + binge” (i.e. “NIAAA model” or “acute-onchronic model) is quickly becoming recognized as a more accurate
representation of human alcohol abuse, particularly risky drinking behavior. This
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model has been used extensively to study the development and progression of
alcoholic (steato)hepatitis. However, the effects of acute-on-chronic alcohol
exposure on the lung are unknown, although risky drinking behavior is clearly
associated with ALI. Therefore, it is proposed that chronic + binge alcohol
exposure may unmask alcohol-induced pathologies in the lung that are not seen
with other, more moderate patterns of alcohol exposure. The goals of the
second Aim of this dissertation are therefore 1) to characterize lung injury and/or
inflammation in this clinically relevant model of alcoholic exposure, 2) to
determine if acute-on-chronic alcohol exposure causes functional effects in the
lung, and 3) to determine if alcohol exposure alone, absent any secondary injury
is sufficient to cause pulmonary inflammation.

3. Establishing a transgenic animal system to investigate
communication between the liver and lung during alcohol exposure

Recent work from this group has demonstrated that the liver and lung not
only share parallel mechanisms of alcohol-induced injury, but that hepaticderived cytokines (TNFα) may, at least in part, contribute to lung injury. This
group showed that EtOH-fed mice that were co-treated with etanercept, a TNFα
inhibitor, showed significantly attenuated lung injury after LPS injection.
However, these data are only suggestive of a liver-lung axis in alcohol-induced
organ toxicity. The third Aim of this dissertation will build on these findings by
attempting to develop an inducible transgenic animal in which genes of interest,
(e.g., TNFα converting enzyme (TACE)) may be selectively deleted from hepatic
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macrophages, thereby providing a mechanism to definitively test the hypothesis
that hepatic-derived inflammatory mediators play a significant role in alcoholenhanced ALI. Furthermore, this transgenic system will have limitless
applications in a wide variety of disease models. The goals of this Aim are
therefore 1) to identify a drug-delivery method which selectively targets the liver
versus the lung, and 2) to develop a transgenic animal to demonstrate the
feasibility of selectively inducing a transgene in the liver versus the lung.

Overall aim of this dissertation

The overall aim of this dissertation is to expand on the unifying hypothesis
that not only do the liver and lung share parallel mechanisms of injury in
response to alcohol exposure, but that injury in these two systems may be
interdependent. For example, dysregulation of fibrinolysis has been
demonstrated to be critical in the development of alcohol-induced liver injury, as
well as in various models of ALI. However, the effect of PAI-1 and subsequent
fibrin accumulation on alcohol-enhanced ALI is not known. This question will be
addressed in Aim 1. Additionally, recent data from this group, as well as others,
have suggested that communication between the liver and lung, possibly via
hepatic-derived inflammatory cytokines like TNFα, may contribute to alcoholenhanced injury and inflammation in the lung. The pulmonary effects of a wellestablished, relevant model of alcoholic liver disease, would therefore be of
interest to establish. This question will be the primary goal of Aim 2 of this
dissertation. Finally, although recent data with the TNFα inhibitor etanercept
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suggests that hepatic-derived TNFα contributes to alcohol-enhanced ALI, an
empirical system by which to address this mechanistic link remains
unestablished. Aim 3 will seek to establish an inducible transgenic animal model
to interrogate this hypothesis. Taken together, this dissertation will build novel
insight in the liver-lung axis of disease.
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CHAPTER II

EXPERIMENTAL PROCEDURES

A.

Animals and Treatments
Mice were housed in a pathogen-free barrier facility accredited by the

Association for Assessment and Accreditation of Laboratory Animal Care, and
procedures were approved by the University of Louisville’s Institutional Animal
Care and Use Committee.

1. Animal sacrifice, tissue collection and storage
At time of sacrifice, animals were anesthetized with ketamine/xylazine
(100/15 mg/kg, i.p.). Blood was collected from the vena cava just prior to
sacrifice by exsanguination and citrated plasma was stored at -80 ˚C for further
analysis. Prior to lavage of the lungs, 10 mL of sterile PBS was perfused through
the heart to flush the pulmonary vasculature of erythrocytes. Bronchoalveolar
lavage (BAL) was performed by flushing the lung two times with 400 μL sterile
PBS. Cells in the BALF were separated by centrifugation and removed from
remaining BALF and fixed on slides for further analysis (88). Portions of tissue
(liver, lung, kidney, and spleen) were snap-frozen in liquid nitrogen for later
analysis or fixed in 10% neutral buffered formalin for subsequent sectioning and
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mounting on microscope slides Total RNA was immediately extracted from fresh
lung tissue using RNA STAT-60 (Tel-Test, Inc., Friendswood, TX) and
chloroform:phenol separation (see section D for additional details).

2. Chronic model of alcohol exposure
Eight week old male C57BL6/J, Pai-1 knockout (B6.129S2Serpine1tm1Mlg/J: PAI-1−/−), and integrin β3 knockout (B6.129S2-Itgb3tm1Hyn/JSemJ:
β3-/-) mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and
exposed to either ethanol-containing Lieber-DeCarli diet (Dyets, Inc., Bethlehem,
PA) or iso-caloric control diet. During the exposure period, animals were housed
in pairs in shoebox cages in a room held at 75 ˚F. Diet was provided in vacuum
tubes and replaced between 4:00 and 5:00 PM daily. Both ethanol-fed animals
and their pair-fed counterparts received control diet for the first two days of liquid
diet feeding to allow acclimation to the liquid diet feeders. After 2 days of
acclimation, ethanol concentrations were increased incrementally over the
course of three weeks before reaching the highest ethanol concentration, 6%
(vol/vol) for the final three weeks of exposure. Ethanol concentrations in the
ethanol-containing diets were as follows: 0% for two days of acclimation, 1% for
two days, 2% for two days, 4% for one week, 5% for one week, and 6% for three
weeks. Ethanol-containing diet was provided ad libitum for the entire course of
the study. Because of the relatively high caloric content of ethanol, pair-fed
control animals received an iso-caloric control diet; the calories in the iso-caloric
diet were matched by adding a calorie-equivalent of maltose-dextran. To
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account for the reduced food consumption of ethanol-fed mice, pair-fed mice
were given the volume of diet consumed by their ethanol-fed counterparts the
night before. At the conclusion of the feeding period, the two diet groups were
further separated into additional groups that received either LPS (E. coli; 10
mg/kg i.p Sigma-Aldrich, St. Louis, MO) or vehicle (saline). Animals were
euthanized 4 or 24 h after LPS (or vehicle) injection, and samples were collected
as described in section A1.

3. Chronic + binge model of alcohol exposure
Ten-week-old C57Bl6/J mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). Mice were treated as described by Bertola et al
(80). During the exposure period, animals were housed in pairs in shoebox
cages in a room held at 75 ˚F. Diet was provided in vacuum tubes and replaced
between 4:00 and 5:00 PM daily. Animals were acclimatized to control (0%
EtOH) Lieber-DeCarli liquid diet (Dyets, Inc., Bethlehem, PA) for 5 days. Mice
were then split into two groups to ethanol-containing (5% v/v) or iso-caloric
control liquid diet for 10 days. To account for the reduced food consumption of
ethanol-fed mice, pair-fed mice were given the volume of diet consumed by their
ethanol-fed counterparts the night before. On day 11, mice received ethanol (5
g/kg) or iso-caloric maltose dextran binge via oral gavage. Mice were sacrificed
9 or 24 hours post-binge. Tissues were collected as described in section A1.
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4. Generation of transgenic mice
Female mice homozygous for tamoxifen-inducible Cre recombinase
(B6;129-Gt(ROSA)26Sortm1(cre/ERT)Nat/J or simply, R26CreER) and male mice
homozygous for a two-color fluorescent Cre reporter allele (B6.129(Cg)Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J, or simply ROSAmT/mG) were purchased
from the Jackson Laboratory (Bar Harbor, ME). The two-color fluorescent
reporter allele used in these experiments, also known as ROSAmT/mG expresses
cell membrane-targeted red fluorescence (tdTomato) ubiquitously prior to
exposure to Cre recombinase. Upon Cre-mediated recombination, the tdTomato
cassette, which is flanked by lox-p sites, is excised, allowing for expression of
membrane-targeted enhanced green fluorescent protein (EGFP) located
downstream.
Female homozygous R26CreER mice were crossed with male ROSAmT/mG
mice at 8-10 weeks of age to produce mice heterozygous for these two
transgenes (R26CreER+/mTmG+, F1 generation). All pups were weaned at postnatal day 21. Animals used in future experiments were between 6-12 weeks of
age.

5. Intraperitoneal administration of tamoxifen
Tamoxifen (Sigma-Aldrich, St. Louis, MO) was injected in
R26CreER+/mTmG+ mice according to a protocol described by The Jackson
Laboratory (Bar Harbor, ME). Briefly, tamoxifen was dissolved in corn oil (20
mg/mL) by shaking overnight in a light-protected vessel at 37 ˚C. Tamoxifen was
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then injected at a final concentration of 75 mg/kg*bw once every 24 hours for a
total of 5 consecutive days. Mice were sacrificed 7 days after the final injection
as described in Section A.1 and B.6.

6. Intravenous administration of tamoxifen-loaded PLGA nanoparticles
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles were prepared in 200 µL
sterile saline at a final concentration of 1.5 mg nanoparticles per 25 g of body
weight. Just prior to injection, nanoparticles were sonicated in a water bath
sonicator for 1 minute to break up any nanoparticle clusters. Mice were
restrained, and nanoparticles were injected with a 28 gauge insulin syringe in the
tail vein after warming the tail with a heat lamp. Mice were sacrificed 7 days after
the final injection as described in Section A.1 and B.6.

7. Intrasplenic administration of tamoxifen-loaded PLGA nanoparticles
PLGA nanoparticles were administered via intrasplenic injection in mice as
described elsewhere (89) under aseptic conditions. Briefly, mice were
anesthetized with inhaled isofluorane and abdominal hair was removed. After
laparotomy, the spleen was visualized and PLGA nanoparticles were injected
with a 28 gauge insulin syringe at a dose of 0. 0.375, 0.75, or 1.5 mg per 25 g of
body weight in 200 µL sterile saline. Just prior to injection, nanoparticles were
sonicated in a water bath sonicator for 1 minute to break up any nanoparticle
clusters. Antibiotics (penicillin [10,000 Units/mL] streptomycin [10,000 µg/mL])
(Life Technologies, Carlsbad CA) were administered intraperitoneally (50 µL) and
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the incision was closed using 3-0 silk sutures. Animals were singly housed after
the procedure and sacrificed as described in Section A.1 7 days later. Tissues
were collected as described in Section A.1 and B.6.

B.

Histology
1. General morphology
Formalin fixed, paraffin embedded liver and lung tissues were cut at 5 μm

and mounted on charged glass slides. Sections were deparaffinized with
Citrisolv (Thermo Fisher Scientific, Waltham, MA) and rehydrated through graded
ethanol. Sections were then stained with hematoxylin and eosin (H&E). After
staining, samples were dehydrated through graded alcohol, washed in Citrisolv
and then mounted with Permount (Thermo Fisher, Waltham, MA).

2. Scoring of alveolar septal thickening
Twenty blinded photomicrographs per sample of hematoxylin and eosinstained paraffin embedded lung tissues were taken in successive fields at 400x
magnification and saved. Four randomly selected alveolar septa per photograph
were measured using the straight line tool on ImageJ software (90). Resulting
measurements are given as length of the straight line pixels and represented as
fold of control. As per guidelines established by the American Thoracic Society,
areas of the tissue that were underinflated during histological preparation were
avoided, as this may cause the septa to appear artificially thickened (29).
Additionally, septa directly adjacent to a blood vessel or airway were avoided, as
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these septa are normally thickened by collagen present in the
peribronchovascular bundle (29).

3. Neutrophil accumulation
Neutrophil accumulation in lung tissue was measured using chloracetate
esterase (CAE) staining. Briefly, formalin fixed, paraffin embedded lung tissue
was cut at 5 μm and mounted on charged glass slides. Sections were
deparaffinized with Citrisolv (Thermo Fisher Scientific, Waltham, MA) and
rehydrated through graded ethanol. Tissue specimens were incubated in a
solution of napthol AS-D chloroacetate (1 mg/ml) in N,N-dimethylformamide, with
4% sodium nitrite and 4% new fuchsin (Sigma-Aldrich, St. Louis, MO). The
napthol AS-D chloroacetate is enzymatically hydrolyzed by chloroacetate
esterase in neutrophils, liberating the napthol compound. Napthol combines with
a freshly-formed diazonium salt, leaving bright pink color deposits at the site of
enzymatic activity (University of Calgary Airway Inflammation Research Group).

4. Immunohistochemistry
Immunohistochemistry for CD41 was performed by the Michigan State
University Investigative Histopathology Laboratory. Previously sectioned slides
were subsequently de-paraffinized in xylene and hydrated through descending
grades of ethyl alcohol to distilled water. Slides were placed in Tris Buffered
Saline pH 7.4 (Scytek Labs, Logan, UT) for 5 minutes for pH adjustment.
Following TBS, slides underwent heat retrieval utilizing Scytek Citrate Plus
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Retrieval pH 6.0 in a vegetable steamer for 30 minutes at 100 C, allowed to cool
on the counter at room temperature for 10 minutes and rinsed in several changes
of distilled water. Endogenous Peroxidase was blocked utilizing 3% Hydrogen
Peroxide / Methanol bath for 30 minutes followed by running tap and distilled
water rinses. Following pre-treatment standard micro-polymer complex staining
steps were performed at room temperature on the IntelliPath™ Flex Autostainer.
All staining steps are followed by rinses in TBS Autowash buffer (Biocare
Medical, Concord, CA). After blocking for non-specific protein with Background
Punisher (Biocare) for 5 minutes; sections were incubated with Rabbit Polyclonal
anti - CD41/integrin αIIB (Abcam ab83961, Cambridge, MA) @ 1:100 in normal
antibody diluent (NAD-Scytek) incubated for 2 hours. Mach 3 Probe and Mach 3
Polymer™ anti rabbit reagents (Biocare) were applied for 10 minutes each
followed by reaction development utilizing Romulin AEC™ (Biocare) for 5
minutes and counterstain with (Biocare) Cat Hematoxylin for 5 minutes. Slides
were visualized on a Nikon Eclipse E600 microscope (Nikon Corporation, Tokyo,
Japan), and DAB staining was quantified in ten high-magnification (400x) fields
using Metamorph software (Molecular Devices, Sunnyvale, CA).
Green fluorescent protein (GFP) was detected immunohistochemically in
liver and lung sections. Previously sectioned formalin-fixed, paraffin-embedded
liver and lung sections were deparaffinized and heat-mediated antigen retrieval
was performed in 0.01 M sodium citrate (pH 6.0) in a vegetable steamer.
Following antigen retrieval, endogenous peroxidases were quenched in 3%
hydrogen peroxide. Blocking for endogenous biotin was performed using a
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commercially available kit (Agilent Technologies, Santa Clara, CA). Prior to
applying primary antibody, sections were blocked in 10% goat serum in PBS.
Sections were incubated in 1:200 rabbit anti-GFP (Cell Signaling Technologies
2956S, Danvers, MA) overnight at 4 ˚C. The Vectastain Elite ABC kit was used
for detection (Vector Laboratories, Inc., Burlingame, CA). Briefly, tissues were
incubated in a biotinylated anti-rabbit IgG secondary antibody for 30 minutes at
room temperature. Tissues were washed and incubated in a solution containing
avidin-bound horseradish peroxidase (HRP) for 30 minutes. The HRP substrate
3, 3’-diaminobenzidine (DAB) (Agilent Technologies, Santa Clara, CA) was
added to sections until positive (brown) staining was macroscopically visible.
Slides were counterstained with hematoxylin for 1 minute, washed, dehydrated
through graded ethanol and then mounted with Permount (Thermo Fisher,
Waltham, MA). Each slide contained a negative tissue section that did not
receive primary antibody. Slides were visualized using a Nikon Eclipse E600
microscope (Nikon Corporation, Tokyo, Japan) with Metamorph software
(Molecular Devices, Sunnyvale, CA).

5. Immunofluorescence
Immunofluorescent detection of fibrin accumulation has been described
previously (38), and was conducted with minor modifications. Previously
sectioned lung tissues (5 µM) were deparaffinized with Citrisolv (Thermo Fisher,
Waltham, MA) and rehydrated through graded ethanol. To quench
autofluorescence of paraffin-embedded tissue, tissue sections were incubated in
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70% EtOH containing 0.25% NH4OH for 1 hour at room temperature during
deparaffinization. Proteolytic digestion was performed by incubating
deparaffinized tissue sections using 0.03% Pronase E (Sigma-Aldrich, St. Louis,
MO) for 10 minutes at 37˚ C, then sections were incubated in sodium
borohydride (10 mg/mL) for 40 minutes at room temperature for additional
autofluorescence quenching. To minimize non-specific binding of the antibody,
sections were incubated in 10% goat serum in PBS for 30 minutes at RT.
Sections were then incubated with rabbit polyclonal anti-fibrinogen (Agilent
Technologies A0080, Santa Clara, CA) in blocking buffer (1:1000) overnight at 4
˚C. After washing in PBS, sections were incubated with AlexaFluor 488 goat
anti-rabbit secondary antibody (1:500) (Life Technologies, Carlsbad, CA) in
blocking buffer for 3 hours at RT. After washing, slides were mounted with
VECTASHIELD Antifade Mounting Medium with DAPI (Vector Labs, Burlingame
CA). Slides were visualized a Nikon Eclipse E600 microscope (Nikon
Corporation, Tokyo, Japan) with Metamorph software (Molecular Devices,
Sunnyvale, CA).

6. Visualization of red and green fluorescence in frozen tissue sections
For visualization of TdTomato red fluorescent protein (RFP) and enhanced
green fluorescent protein (EGFP) native fluorescence in tissues, mice were
perfused through the heart with ice cold 4% paraformaldehyde (PFA) in 0.1 M
PBS. Tissues were fixed in 4% PFA in 0.1 M PBS for 24 hours. After fixing,
tissues were cryoprotected in 30% sucrose solution for 24 hours, then embedded
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in Tissue-Plus Optimal Cutting Temperature (OCT) embedding medium (Thermo
Fisher, Waltham MA) by freezing in liquid nitrogen. After embedding, samples
were allowed to come to -20 ˚C and sectioned at 5 µM on a Leica cryostat.
Sections were air-dried for 1 hour at RT, washed 3 times in PBS, and mounted
with VECTASHIELD Antifade Mounting Medium with DAPI (Vector Labs,
Burlingame CA). Slides were visualized using a Nikon Eclipse E600 microscope
(Nikon Corporation, Tokyo, Japan) with Metamorph software.

7. Differential staining of BAL cells
Cells in BAL fluid were counted using a hemocytometer, and cells were
spun onto glass slides using a Cytospin centrifuge (Thermo Fisher Scientific,
Waltham, MA). Cells were stained with the Shandon Kwik-Diff (Thermo Fisher
Scientific, Waltham, MA) differential staining kit according to manufacturer’s
instructions. Slides were visualized on a Nikon Eclipse E600 microscope (Nikon
Corporation, Tokyo, Japan) with Metamorph software (Molecular Devices,
Sunnyvale, CA), and total number of cells in 2 low-magnification (100x) fields
were counted using ImageJ software.

C.

Clinical chemistry
1. Plasma transaminase activity
Plasma activity levels of alanine aminotransferase (ALT) and aspartate

aminotransferase (AST) were determined spectrophotometrically using standard
kits (Thermo Fisher Scientific, Waltham, MA).
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2. Myeloperoxidase Activity
Myeloperoxidase activity was measured as previously described (91, 92).
Frozen lung tissue samples were thawed and homogenized in 50 mM potassium
phosphate buffer (pH 6.0), then centrifuged at 9000 x g for 15 minutes at 4˚C.
Supernatant (containing hemoglobin) was discarded, and the resulting pellet was
resuspended in potassium phosphate buffer (pH 6.0) containing 50 mM
hexadecyltrimethylammonium bromide (HTAB) and homogenized again. This
suspension was sonicated, and snap frozen in liquid nitrogen and thawed for
three freeze-thaw cycles. Samples were then centrifuged at 9000 x g for 10
minutes at 4˚C. The resulting supernatant was then assayed
spectrophotometrically for myeloperoxidase activity in 50 mM potassium
phosphate (pH 6.) with 0.0005% hydrogen peroxide and 0.167 mg/mL odianisidine dihydrochloride (substrates of myeloperoxidase) at 450 nm. Results
are reported as rate of reaction per mg of lung tissue.

3. BALF total protein measurement
BALF from treated animals was collected as described previously. Total
protein in BALF was measured spectrophotometrically using a modified Lowry
Assay (Bio-Rad DC Protein Assay, Bio-Rad Laboratories, Hercules CA)
according to manufacturer’s instructions.
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4. ELISA
Plasma thrombin-antithrombin (TAT) complex levels were detected in
citrated plasma as previously described (38, 93) using a commercially available
ELISA kit (Dade Behring Inc., Deerfield, IL).

D.

RNA Isolation and Quantitative Reverse-Transcription Polymerase
Chain Reaction
Total RNA was extracted from lung tissue by a guanidinium thiocyanate-

based method (RNA STAT-60, Tel-Test, Inc., Friendswood, TX). RNA
concentrations were determined spectrophotometrically and 1µg of total RNA
was reverse transcribed using a kit (Quantabio, Beverly, MA).
The pulmonary mRNA expression of select genes was detected by
quantitative reverse-transcription polymerase chain reaction (qRT-PCR), which is
routine for the Arteel group (38). PCR primers and probes for Tnf-α, Pai-1, Il-6,
and Il-1β were designed using Primer 3 (Whitehead Institute for Biomedical
Research, Cambridge MA). Primers and probes for Icam-1, Vcam-1,
Pecam/Cd31, Cxcl2, Cxcl1, F4/80, Cxcl15, Ly6g, Cd68, and β-actin were
purchased from Life Technologies (Carlsbad, CA). All primers were designed to
cross introns and ensure that only cDNA and not genomic DNA was amplified.
PerfeCta qPCR Fast Mix (Quantabio, Beverly, MA) was added to the PCR
mixture. This 2X mixture is optimized for TaqMan reactions and contains MgCl2,
dNTPs, and AccuFast Taq DNA Polymerase. Amplification reactions were
carried out using the ABI StepOne Plus machine and software (Applied
Biosystems, Foster City, CA) with initial holding stage (95˚C for 30 seconds) and
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50 cycles of a 2-step PCR (95˚C for 30 seconds, 60˚C for 20 seconds).
Fluorescent intensity of each sample was measured at each cycle to monitor
amplification of the target gene. The comparative CT method was used to
determine fold changes in mRNA expression compared to an endogenous
reference gene (β-actin). This method determines the amount of target gene,
normalized to an endogenous reference and relative to a calibrator (2 ΔΔCT).

E.

Pulmonary Mechanics Measurements
Pulmonary mechanics at baseline and in response to inhaled

methacholine were measured in mice as described in (94). Measurements were
performed by forced oscillation technique using a flexiVent system (SCIREQ,
Montreal, Quebec, Canada). Mice were anesthetized with tribromoethanol (375
mg/kg i.p.). A cannula connected to a pressure transducer and ventilator was
inserted into the trachea. Mice were placed on a warming plate and attached to
EKG leads, and lungs were mechanically ventilated with air at a tidal volume of 6
ml/kg and a frequency of 150 breaths/min. To prevent endogenous breathing
effort, mice were given pancronium bromide (0.8 mg/kg i.p.) every 20 min until
the completion of airway reactivity measurements. During the experiment, mice
were given additional tribromoethanol to maintain heart rate at or below the
baseline level. Baseline pulmonary mechanics measurements were collected
using 1) a single perturbation at 2.5 Hz to derive resistance and compliance
based on the single compartment model, 2) a broadband perturbation from 1 to
20.5 Hz to derive frequency-dependent impedance and parameters based on the
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constant phase model, and 3) quasi-static pressure-volume curves. Following
baseline assessment, measurements were then repeated following
administration of increasing doses of aerosolized methacholine generated from
solutions of 0, 6.25, 12.5, 25, or 50 mg/mL methacholine. Methacholine was
aerosolized for 10 seconds from an Aeronib nebulizer that delivered 0.15 mL/min
and respiratory parameters were repeatedly collected for a total of 15
measurements of each parameter. For each methacholine dose the average of
15 measurements was collected.

F.

Synthesis of PLGA nanoparticles
PLGA nanoparticles (NPs) encapsulating tamoxifen (Sigma-Aldrich, St.

Louis, MO) were synthesized as previously described, using an oil-in-water (o/w)
single emulsion technique (95-97). Briefly 100 mg tamoxifen was dissolved in 2
mL dichloromethane (DCM). In parallel, 100 mg poly(lactic-co-glycolic acid)
(PLGA) carboxyl-terminated polymer (0.55-0.75 dL/g, LACTEL®, DURECT Corp.)
was dissolved in 1 mL of DCM. The PLGA and tamoxifen (200 µL) solutions were
combined to obtain a final theoretical loading of 200 µg tamoxifen per mg of
PLGA. The PLGA/tamoxifen/DCM solution was added dropwise to a 2 mL 5%
polyvinyl alcohol (PVA) solution, then vortexed and sonicated. Residual DCM
was evaporated by adding the NP solution to 50 mL of 0.3% PVA for 3 hrs while
mixing. After solvent evaporation, the tamoxifen NPs were transferred to tubes
and centrifuged at 20,444 x g at 4°C and washed 3 times in deionized water
(diH2O). NPs were frozen, lyophilized, and stored at -20°C until use.
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G.

Characterization of PLGA nanoparticles
Particle size and morphology were determined using scanning electron

microscopy (SEM, JSM-820, JEOL). Dry NPs were mounted on carbon tape and
sputter-coated with gold under vacuum. The average unhydrated NP diameters
were determined from SEM images of at least 200 particles per batch using
ImageJ image analysis software.
The amount of tamoxifen encapsulated within the NPs was quantified by
dissolving 3-5 mg tamoxifen NPs and control blank NPs in dimethyl sulfoxide
(DMSO) for 30 min. Subsequent dilutions were done to obtain samples within the
linear range of a free tamoxifen standard in DMSO. The loading of tamoxifen,
defined as the amount of tamoxifen incorporated per milligram of NP, was
measured using UV absorption spectroscopy at 265 nm. Background
measurements of blank NPs in DMSO were subtracted from tamoxifen NP
sample

readings.

Encapsulation

efficiency,

or

the

percent

Tamoxifen

incorporated relative to the amount of tamoxifen initially loaded, was calculated
as follows: [(Mass of tamoxifen incorporated per mg of NP) / (Mass of tamoxifen
initially added to electrospinning solution per mg of NP)] x 100.
To determine the release profiles of the tamoxifen in vitro, triplicate NP
samples of 3-5 mg were suspended in 1 mL PBS. NP samples were incubated at
37°C and constantly shaken. At each of the following time points: 1, 4, 8, 24, 48,
72, and 168 hrs, NPs were centrifuged to obtain a pellet (13,000 rpm), and the
complete volume of PBS was removed and replaced with fresh PBS. Tamoxifen
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released into PBS was quantified using absorption spectroscopy at 265 nm. All
samples were analyzed in triplicate.

H.

Statistical Analyses
Results are reported as means ± standard error (SEM). Unless otherwise

specified, one-way or two-way ANOVA with Bonferroni’s post-hoc test (for
parametric data) or was used for the determination of statistical significance
among multiple treatment groups, as appropriate. A p value less than 0.05 was
selected before the study as the level of significance.
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CHAPTER III2

PLASMINOGEN ACTIVATOR INHIBITOR 1 PLAYS A CRITICAL ROLE IN
ALCOHOL-ENHANCED ACUTE LUNG INJURY IN MICE2

A.

Introduction
Alcohol consumption is a common custom worldwide. In the United

States alone, 87.6% of adults report consuming alcohol at some point in their
lives (98). This widespread consumption of alcohol continues, despite the fact
that the detrimental health effects of alcohol abuse are well-established. In fact,
alcohol is known to contribute to the development of over 200 disease states
(99), making alcohol the fifth leading risk factor for premature death and disability
worldwide (100). The lung is recognized as a target of chronic alcohol abuse,
and alcohol-related lung injury is estimated to account for tens of thousands of
deaths in the United States each year (18). Although chronic alcohol
consumption is not directly linked to the development of lung disease per se, it
appears to sensitize the lung to damage from other causes. For example, acute
respiratory distress syndrome (ARDS), the most severe form of acute lung injury
(ALI), occurs 3.7 times more often in people meeting the diagnostic criteria for
alcohol use disorders, and these patients have a worse prognosis (19-21).

2

Published in Poole LG et al. Am J Respir Cell Mol Biol. 2017 Apr 26. Reprint with permission.
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The exact mechanisms by which alcohol sensitizes the lung to ALI are
incompletely understood. Although alcohol does not appear to directly cause
overt histologic injury to the lung, experimental alcohol exposure induces
expression of pro-inflammatory cytokines (22-24), activates tissue remodeling
(26, 27), and increases oxidative stress in rodent lungs (28). These factors are
hypothesized to contribute to the development of an “alcoholic lung” phenotype,
which enhances the host’s susceptibility to serious lung diseases (18). Better
understanding of this complex process could identify potential therapeutic targets
to treat or prevent alcohol-related lung dysfunction, including enhanced
susceptibility to ALI and ARDS.
Plasminogen activator inhibitor-1, or PAI-1, is a key regulator of the
fibrinolytic system. PAI-1 is an acute phase protein normally expressed by
adipocytes and endothelial cells, but is inducible in other cell types, including
macrophages, during times of inflammation and/or stress (45). PAI-1 is readily
induced by almost all stress signaling, including hypoxia, oxidative stress and
inflammatory cytokines (101). PAI-1 is the primary physiological inhibitor of
fibrinolysis. PAI-1 inhibits tissue-type plasminogen activator and urokinase-type
plasminogen activator (tPA and uPA, respectively), enzymes that convert
plasminogen to plasmin, which degrades fibrin. The Arteel group has
demonstrated that PAI-1 is critical in experimental inflammatory liver injury
caused by alcohol (38, 46). PAI-1 also plays a critical role in experimental ALI
(54), and is a suspected to contribute to the incidence and severity of ARDS in
humans (50, 52). However, the contribution of PAI-1 in alcohol-enhanced ALI
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has not been determined. The purpose of this study was to determine the role of
PAI-1 in alcohol-enhanced inflammatory lung injury caused by LPS.

B.

Experimental Procedures
1. Animals and treatments
Animals were administered ethanol-containing Lieber-Decarli liquid diet for

6 weeks and injected with LPS (See Scheme 1.1) as described in Chapter II,
Section A.2. Upon sacrifice, tissues were collected as described in Chapter II,
Section A.1.

2. Histology
Lung tissues were stained with hematoxylin and eosin for general
morphology and scored as described in Chapter II, Sections B.1 and B.2
Neutrophil accumulation in tissues were visualized with chloracetate esterase
staining as described in Chapter II, Sections B.3. CD41 and Fibrin were detected
in paraffin-embedded lung sections as described in Chapter II, Sections B.4 and
B.5.

3. Clinical chemistry
BALF total protein levels were measured as described in Chapter II,
Section C.3. Plasma thrombin anti-thrombin (TAT) was detected using a
commercially available ELISA kit, as described in Chapter II, Section C.4.
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Myeloperoxidase activity in lung tissue was measured as described in Chapter II,
Section C.2.

4. RNA Isolation and qRT-PCR
Details for RNA isolation and qRT-PCR are described in Chapter II,
Section D.
5. Statistical analysis
Statistical analysis was performed as described in Chapter II.

C.

Results
1. Chronic ethanol feeding enhances pulmonary PAI-1 expression and
fibrin accumulation caused by LPS.
PAI-1 is proposed to play a role in models of ALI in the absence of alcohol

(53, 54). Furthermore, PAI-1 is critically involved in alcohol-induced liver injury
(47). Therefore, animals were treated with chronic ethanol-containing diet and
LPS as described in Chapter II (Scheme 3.1.), and the effects of ethanol and
LPS on pulmonary PAI-1 expression were determined (Figure 3.1A). LPS
administration robustly increased the expression of Pai-1 mRNA (~1000 fold,
p<0.05) in the lungs. Although, ethanol feeding alone did not affect Pai-1
expression, it significantly enhanced the increase in Pai-1 expression caused by
LPS, with values ~2-fold higher than with LPS alone. PAI-1 protein levels in the
BAL fluid (24 h after LPS) paralleled the pattern of mRNA expression (Figure
3.1A).
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Scheme 3.1: Lieber-DeCarli model of chronic alcohol exposure and
experimental endotoxemia
Mice received ethanol-containing or isocaloric maltose-dextrin containing
Lieber-DeCarli diet (see Experimental Procedures) for six weeks and were
injected with LPS (10 mg/kg i.p.) or vehicle (saline) 4 or 24 hours prior to
sacrifice.
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Figure 3.1. Effect of ethanol on LPS-induced pulmonary PAI-1 expression
and pulmonary fibrin accumulation.
Pulmonary Pai-1 mRNA expression measured by qRT-PCR and PAI-1 protein
levels in BAL fluid. (B) Representative photomicrographs (400×) of pulmonary
fibrin deposition detected immunofluorescently (green) in paraffin-embedded
tissues 24 h after LPS injection. Results are reported as means ± standard
error mean (SEM; n= 4-6), a, p < 0.05 compared to pair-fed control, b, p < 0.05
compared to LPS alone, c, p < 0.05 compared to WT animals. Appears in
Poole LG et al. Am J Respir Cell Mol Biol. 2017 Apr 26. DOI:
10.1165/rcmb.2016-0184OC, reprinted with permission.

45

A

PAI-1 mRNA Expression

a,b

Fold of Control

2000

12

BAL PAI-1
a,b

10
8

1500
a

a
6

1000
4
500

2

1
0

EtOH LPS -

0

+
-

+

+
+

-

+
-

+

EtOH

Pairfed
Plot 1

LPS24h
LPS,

Control

B

46

+
+

As the canonical inhibitor of urokinase-type plasminogen activator and
tissue-type plasminogen activator, PAI-1 induction prevents the degradation of
fibrin by plasmin. Therefore, fibrin accumulation in lung tissue was also
measured. Figure 3.1B shows representative photomicrographs of lung tissue
stained immunofluorescently for fibrin. LPS administration caused fibrin to
accumulate in both vascular and extravascular tissue in the lung 24 h after LPS.
There was no detectable effect of LPS on this variable at the 4 h time point (not
shown). In contrast, ethanol feeding alone did not affect pulmonary fibrin
deposition; however, it enhanced fibrin accumulation caused by LPS
administration (Figure 3.1B).

2. PAI-1 deficiency blocks alcohol-enhanced pulmonary fibrin
deposition and LPS-induced pulmonary platelet accumulation.
Fibrin may accumulate at sites of injury via enhanced activation of the
coagulation cascade (i.e., thrombin activation), or by impaired fibrinolysis (i.e.,
PAI-1 induction). Therefore, the effect of PAI-1 deficiency on activation of the
coagulation cascade was determined. In the current study, ethanol pre-exposure
enhanced Pai-1 expression in the lung after LPS exposure, and this enhanced
Pai-1 expression correlated with increased deposition of fibrin in lung tissue
(Figure 3.1A and 3.1B). LPS administration significantly increased plasma TAT (4
h after injection) by 7-fold, indicating activation of the coagulation cascade
(Figure 3.2A). Ethanol feeding alone did not significantly enhance plasma TAT;
however, ethanol significantly enhanced the increase caused by LPS
administration, with values ~13-fold over control. Interestingly, PAI-1 deficiency
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Figure 3.2. Effect of PAI-1 deficiency on pulmonary fibrin accumulation
and platelet accumulation.
(A)

Plasma thrombin anti-thrombin (TAT) levels. (B) Representative

photomicrographs

(400x)

of

pulmonary

fibrin

deposition

detected

immunofluorescently in paraffin-embedded tissues 24 h after LPS injection.
(C).

Representative

photomicrographs

(400x)

of

platelets

detected

immunohistochemically in paraffin-embedded sections via integrin αIIB (CD41)
4 h after LPS injection. (D) Quantitative image analysis of CD41-positive
staining. Results are reported as means ± standard error mean (SEM; n= 4-6),
a,

p < 0.05 compared to pair-fed control, b, p < 0.05 compared to LPS alone, c,

p < 0.05 compared to WT animals. Appears in Poole LG et al. Am J Respir Cell
Mol Biol. 2017 Apr 26. DOI: 10.1165/rcmb.2016-0184OC, reprinted with
permission.
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dramatically attenuated pulmonary fibrin deposition (Figure 3.2B), despite plasma
TAT being unchanged in knockout animals (Figure 3.2A).
One potential mechanism by which fibrin matrices can be proinflammatory is by contributing to platelet aggregation. Fibrin can drive platelet
aggregation at sites of injury, and in turn, the platelets themselves may
propagate injury (102). Therefore, platelet accumulation in lung tissue was
determined immunohistochemically by detecting the platelet-specific integrin
αIIBβ3 and subsequently performing quantitative image analysis (Figure 3.2C and
3.2D). Ethanol feeding alone had no significant effect on platelet accumulation
(CD41-positive staining), and LPS administration significantly enhanced platelet
accumulation in lung tissue. LPS-induced platelet accumulation was not affected
by ethanol pre-exposure. PAI-1 deficiency prevented platelet accumulation in
lung tissue after LPS administration.

3. PAI-1 deficient mice are protected from alcohol-enhanced edematous
lung injury caused by LPS.
The results described in Figures 3.1 and 3.2 suggest that ethanol feeding
enhances LPS-induced fibrin deposition at least in part by super-inducing PAI-1
expression (Figure 3.1A and 3.2B). Additionally, Figure 3.2C indicates that PAI-1
is critical for LPS-induced platelet aggregation in lung tissue. Previous studies
indicate that PAI-1 contributes to inflammatory damage to the lungs (53, 54), as
well as other organs (e.g., liver) (38), and that platelet aggregation is involved in
the development of ALI (103). It is also known that chronic ethanol feeding
sensitizes the lung to endotoxemia-induced ALI and enhances edematous lung
50

injury (e.g.,(28, 104)). Therefore, the effect of PAI-1 deficiency on alcoholenhanced experimental ALI was determined.
There was no significant effect of diet or genotype on growth of animals
over the six week feeding period (not shown). Additionally, neither ethanol preexposure nor genotype affected attrition after LPS injection. As expected (104),
extrathoracic LPS administration caused pulmonary injury and inflammation, as
indicated by extravasation of erythrocytes (4 h after LPS, data not shown) and
inflammatory cells (4 h after LPS) [Figure 3.3A (insets) and 3.3B]. At the 4 h time
point, there was no discernable effect of ethanol pre-exposure on LPS-induced
injury. Additionally, ethanol feeding was associated with pulmonary edema 24
hours after LPS administration, as indicated by an increase in BAL total protein
content (Figure 3.3C) and enhanced thickening of the alveolar septa (Figure
3.3D). The increase in BAL protein and in septal thickening caused by the
interaction of ethanol and LPS was completely attenuated in PAI-1-/- mice
compared to wild-type (Figure 3.3A, bottom panels, Figure 3.3C, and 3.3D). LPS
administration increased the number of pulmonary neutrophils, as indicated by
an increase in MPO activity (Figure 3.3B). Ethanol exposure did not significantly
alter the increase in MPO activity caused by LPS.

4. Alcohol enhances LPS-induced cytokine/chemokine expression;
effect of PAI-1 or integrin β3 deficiency.
The results of the current study indicate that PAI-1 deficiency attenuates
alcohol-enhanced pulmonary fibrin deposits and platelet accumulation, and also
protects against alcohol-enhanced acute lung injury. Although the number of
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Figure 3.3: Effect of PAI-1 deficiency on ethanol-enhanced ALI.
(A) Representative photomicrographs (400×, hematoxylin & eosin) of formalinfixed paraffin-embedded lung tissues 24 h after LPS and CAE staining (inset,
800×). Neutrophils are shown as bright pink cells (4 h after LPS). (B)
Pulmonary MPO activity 4 h after LPS. (C) BAL total protein content 24 h after
LPS. (D) Quantification of alveolar septal thickening, as described in Materials
and Methods, 24 h after LPS. Results are reported as means ± standard error
mean (SEM; n= 4-6), a, p < 0.05 compared to pair-fed control, b, p < 0.05
compared to LPS alone, c, p < 0.05 compared to WT animals. Appears in
Poole LG et al. Am J Respir Cell Mol Biol. 2017 Apr 26. DOI:
10.1165/rcmb.2016-0184OC, reprinted with permission.
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infiltrating neutrophils is unaffected by ethanol pre-exposure or PAI-1 deficiency,
the phenotype of recruited inflammatory cells may be influenced by how these
factors affect inflammatory cytokine and chemokine expression (105). Therefore,
the mRNA expression of key inflammatory mediators was measured in whole
lung homogenate (Figure 3.4). Protein levels of cytokines and chemokines
relative to mRNA expression has been validated previously (104). Ethanol alone
did not affect expression of any of the tested cytokines (Tnfα, Il-6, Il-1β; 3.4A),
chemokines (KC (Cxcl1), MIP-2 (Cxcl2); 3.4A) or adhesion molecules (Icam-1,
Vcam-1, Pecam; 3.4A) measured. LPS administration induced expression of all
variables, with the exception of Pecam, which was significantly decreased by
LPS administration (Figure 3.4A). As demonstrated previously (104), ethanol
feeding enhanced the induction of Il-6, Cxcl1 (KC), Cxcl2 (MIP-2), Icam-1, and
Vcam-1 expression caused by LPS. With the exception of Il-6, these effects of
ethanol were significantly attenuated in PAI-1-/- mice, with values in the knockout
strain similar to wild-type mice receiving LPS in the absence of ethanol feeding.
For example, the expression of MIP-2 caused by ethanol/LPS was ~3-fold lower
in PAI-1-/- compared to wild-type mice. In the absence of ethanol pre-exposure,
PAI-1 deficiency did not significantly affect LPS-induced expression of any
mediators measured compared to wild-type animals (Figure 3.4A).
The CXC chemokines, MIP-2 (CXCL1) and KC (CXCL2) are murine
homologues of IL-8. In experimental studies, these chemokines are critical for the
development of ALI (106). In the current study, ethanol feeding enhances
expression of the chemokines MIP-2 and KC, and this effect is significantly
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Figure 3.4: Effect of PAI-1 deficiency and integrin β3 deficiency on LPSinduced cytokine and chemokine expression.
(A) Pulmonary mRNA expression in whole lung homogenate of cytokines,
chemokines, and vascular adhesion molecules measured by qRT-PCR in wildtype and PAI-1 knockout mice treated with ethanol and/or LPS. (B) Pulmonary
mRNA expression of select chemokines measured by qRT-PCR in wild-type or
integrin β3 knockout mice measured by qRT-PCR. Results are reported as
means ± standard error mean (SEM; n= 4-6), a, p < 0.05 compared to pair-fed
control, b, p < 0.05 compared to LPS alone, c, p < 0.05 compared to WT
animals. Appears in Poole LG et al. Am J Respir Cell Mol Biol. 2017 Apr 26.
DOI: 10.1165/rcmb.2016-0184OC, reprinted with permission.
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attenuated in PAI-1 deficient mice (Figure 3.4A). One potential mechanism that
may drive expression of these CXC chemokines is aggregation of platelets in the
pulmonary vasculature (107). Results in Figure 3.2C indicate that PAI-1
deficiency attenuates LPS-induced platelet aggregation in the lung, which is
mediated, at least in part, by integrin αIIBβ3 binding to fibrin. Therefore, the effect
of β3 integrin deficiency on ethanol-enhanced expression of the chemokines MIP2 and KC in whole lung homogenate were determined (Figure 3.4B). The
enhanced induction of pulmonary MIP-2 and KC caused by the interaction of
ethanol and LPS exposure was completely attenuated by β 3 deficiency.
Interestingly, the super-induction of PAI-1 caused by this interaction was also
completely attenuated (Figure 3.4B). Markers of other integrin β3-expressing
cells, such as Th17 cells (e.g., IL-22 and IL-23), were also measured, and found
to be unaffected by diet or genotype (data not shown). Moreover, the surface
expression of CD41 is altered by β3 deficiency (108), so quantitation of CD41
staining via image analysis was not feasible. However, morphologic assessment
of CD41 staining in β3 knockout mice suggested that β3 deficiency blocks LPSinduced platelet accumulation in the lung after ethanol (not shown), similar to
findings in PAI-1 deficient mice (Figure 3.2).

D.

Discussion
Endotoxemia in the setting of sepsis is one of the top causes of acute lung

injury. As mentioned in the Introduction, chronic alcohol exposure is one of the
most clinically important susceptibility factors for this deadly disorder in at-risk
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individuals. The goal of the current study was to investigate the mechanisms
responsible for these events in mice exposed to ethanol chronically (6 weeks)
followed by induction of endotoxemia. Furthermore, this study explored the role
of anti-fibrinolytic PAI-1 and β3 integrins using genetically engineered (i.e.,
knockout) animals.
These studies revealed important and novel observations. First, it was
observed that extrathoracic LPS induced the deposition of fibrin in the lung,
which was associated with elevated PAI-1 levels (Figure 3.1). These effects
were also associated with the accumulation of platelets in the lung (Figure 3.2).
LPS caused inflammatory injury in the lung, as indicated by accumulation of
neutrophils and extravasation of erythrocytes (Figure 3.3), and induced
expression of several pro-inflammatory mediators (Figure 3.4). Second, although
exposure to ethanol alone did not affect these variables, ethanol enhanced LPSinduced PAI-1 expression (Figure 3.1A), pulmonary fibrin deposition (Figure
3.1B) and plasma TAT (Figure 3.2A), and indices of transient lung damage
(Figure 3.3), as well as expression of proinflammatory mediators described
above (Figure 3.4). As such, these studies further strengthen available data
implicating alcohol as a major susceptibility factor in acute lung injury. Third,
PAI-1 deficiency dramatically blunted pulmonary fibrin deposition and platelet
accumulation, as well as attenuated alcohol-enhanced ALI. PAI-1 deficiency also
significantly protected against the alcohol-enhanced expression of inflammatory
mediators (Figures 3.2-4). Finally, mice lacking αIIBβ3, the primary platelet

58

receptor for fibrinogen, displayed a dramatic reduction in early inflammatory
change after alcohol/LPS challenge (Figure 3.4).
In the current study, alcohol enhanced the activation of the coagulation
cascade, as well as induction of PAI-1 (Figures 3.1 and 3.2), both of which are
capable of enhancing fibrin ECM deposition (Figure 3.1). Changes in the amount
and composition of the ECM are well-recognized events in the pathology of endstage diseases (e.g., hepatic cirrhosis and pulmonary fibrosis). However, the
extracellular matrix is a dynamic and responsive entity, and subtle alterations to
the ECM may be involved in inflammatory/pre-fibrotic stages of disease (43).
The term “transitional tissue remodeling” describes qualitative and quantitative
changes of matrix proteins in response to insults that do not alter the overall
architecture of the organ. Recent studies suggest that transitional tissue
remodeling contributes to damage caused/enhanced by alcohol in several
organs, including the liver and the lung (44). The Arteel group has demonstrated
that the hepatic fibrin ECM responds dynamically to alcohol exposure, sensitizing
the liver to LPS-induced inflammatory damage (38). Similarly, chronic alcohol
exposure alters the expression and degradation of the pulmonary ECM, favoring
fibronectin deposition (40). The activation of the coagulation cascade is a key
shared response to acute organ injury that transiently alters the ECM. Although
these changes often revert without any prolonged tissue damage, they have the
potential to alter the immune/inflammatory response to stress.
The finding that knocking out PAI-1 almost completely attenuated alcoholenhanced fibrin deposition in the lung (Figure 3.2B), despite no effect on plasma
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TAT (Figure 3.2A) indicates that PAI-1 induction is critical under these conditions,
regardless of activation of the coagulation cascade. These results are in line with
previous investigations into fibrin and PAI-1 in mouse liver (38). These results
suggest that the half-life of fibrin is regulated predominantly at the level of
fibrinolysis, rather than at the level of deposition. Interestingly, ethanol did not
impact the increase in neutrophil recruitment caused by LPS (Figure 3.3B), but
nevertheless increased injury (Figures 3.3A, 3.3C, 3.3D) and proinflammatory
chemokine expression (Figure 3.4). These results suggest PAI-1/fibrin is
mediating the inflammatory injury rather than inflammatory cell recruitment, per
se. Fibrin matrices contribute to inflammation in many models through several
potential mechanisms [see (101) for review]. For example, fibrin matrices
provide a chemotactic substrate for monocytes and leukocytes and induce
cytokine expression (109).
In addition to physiochemical effects that may enhance inflammatory
injury, fibrin may facilitate recruitment of platelets to sites of injury. Indeed, the
enhanced lung damage caused by the interaction between ethanol and LPS was
associated with an increase in platelet recruitment and/or indices of platelet
activators (i.e., TAT; Figure 4). Impairment of the ability of platelets to bind to
fibrin via integrin αIIBβ3 (such as in the case of β3-/- mice) also prevented injury.
Platelets are known to be involved in many forms of lung injury (102), including
allergic inflammation (110), cystic fibrosis (111), acid aspiration (112), and
importantly for the current study, endotoxemia (113). Platelets adhere to the
pulmonary endothelium after LPS injection (113). After this initial adherence,
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platelets can become more tightly bound and aggregated by activation of integrin
αIIBβ3 by binding to fibrin. Additionally, thrombin can then further activate
platelets via the protease-activated receptors (PARs) (114, 115). Adhered and
activated platelets can promote inflammatory injury by releasing mediators (e.g.,
CD40L) that upregulate expression of chemokines and vascular adhesion
molecules in endothelial cells (107). In the current study, PAI-1-dependent
platelet accumulation was associated with enhanced expression of the
chemokines MIP-2 and KC, as well as vascular adhesion molecules Icam-1 and
Vcam-1 (Figure 3.4); these effects were paralleled by integrin β3 deficiency
(Figure 3.4B), supporting the hypothesis that these are linked events.
Interestingly, PAI-1 appeared to play a dominant role in mediating this effect;
specifically, PAI-1-deficient mice were protected against injury and platelet
accumulation despite not decreasing plasma TAT levels. These effects of
ethanol/LPS represents a hypothesized pathway for the accumulation of fibrin,
platelet recruitment and activation, and the progression of inflammatory injury in
which both PAI-1 and platelet β3 integrins are necessary (Scheme 3.2).
PAI-1, like many acute phase proteins, can act as a “double-edged
sword;” it is required for injury, and in some cases, required for wound healing
and repair. For example, the Arteel group has demonstrated that PAI-1 deficient
animals are protected against both acute and chronic alcohol-induced liver injury;
importantly, injury in these models is inflammatory and relatively low-grade. On
the other hand, PAI-1 deficient mice show exacerbated damage in more robust
models of liver injury, including acetaminophen overdose (116, 117), partial
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hepatectomy (118), and in carbon tetrachloride-induced fibrosis (119). Similarly,
PAI-1 deficiency has been demonstrated to enhance acute lung injury in severe
models of ALI/ARDS, such as intratracheal LPS instillation (120). The studies
presented in this chapter demonstrate that PAI-1 deficient mice are protected
against the enhancing effect of alcohol on extrathoracic endotoxemia induced
acute lung injury, in which injury is less severe than the thoracic injection model.
These data therefore indirectly suggest that PAI-1 may also play dual roles in
lung injury, depending on the severity of that injury.
In summary, the study presented in this chapter has demonstrated a
critical role for PAI-1 in experimental alcohol-enhanced acute lung injury. PAI-1deficient mice were protected against alcohol-enhanced inflammatory lung injury.
It is hypothesized that these effects are mediated, at least in part, through PAI-1induced fibrin accumulation and subsequent platelet aggregation driven via
integrin αIIBβ3. This study provides insight into novel targets for therapy to
prevent the development and/or progression of acute lung injury in at-risk
patients.
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Scheme 3.2: Working hypothesis for the role of PAI-1 in alcohol-enhanced
acute lung injury.
It is hypothesized that excessive accumulation of fibrin after tissue injury and/or
endotoxemia (LPS) can contribute to αIIBβ3-mediated platelet accumulation and
aggregation. Activated platelets can contribute to acute lung injury by many
potential mechanisms, including release of pro-inflammatory cytokines and
chemokines from inflammatory cells and ultimately, enhanced tissue injury.
These

effects

are

dramatically

exacerbated

by

ethanol

pre-exposure.

Interventions designed to block this pathway, such as PAI-1 blockade and β3
integrin inhibition may stop the propagation of injury and promote wound healing.
Appears in Poole LG et al. Am J Respir Cell Mol Biol. 2017 Apr 26. DOI:
10.1165/rcmb.2016-0184OC, reprinted with permission.

63

Working Hypothesis
Alcohol
+
LPS
PAI-1-/Fibrin
Accumulation

β3-/Platelet Recruitment
&
Aggregation

Inflammation
and injury

64

CHAPTER IV

ACUTE-ON-CHRONIC ALCOHOL EXPOSURE PROMOTES PULMONARY
INFLAMMATION AND AFFECTS LUNG MECHANICS

A.

Introduction
The consumption of alcoholic beverages is a common practice throughout

the world. In fact, it has been reported that 87.6% of adults in the United States
will consume alcohol at some point (98). The detrimental health effects of
excessive alcohol consumption have been well-characterized. Alcohol is the fifth
leading risk factor for premature death and disability worldwide (100),
contributing to the development of over 200 disease states (99). Although the
liver is considered to be the major target of alcohol toxicity, alcohol also damages
several distal organs. The lung is recognized as a target of chronic alcohol
abuse, and alcohol-related susceptibility to lung injury is estimated to account for
tens of thousands of deaths in the United States each year (18). Although
chronic alcohol consumption is not directly linked to the development of lung
disease per se, it appears to sensitize the lung to damage from other causes. For
example, acute respiratory distress syndrome (ARDS), the most severe form of
acute lung injury (ALI), occurs 3.7 times more often in people meeting the
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diagnostic criteria for alcohol use disorders, and these patients have a much
worse prognosis (19-21).
Although some of the clinical impacts of alcohol consumption on the lung
are well-described, mechanism(s) by which ethanol impacts pulmonary function
are incompletely understood. These gaps in our knowledge are due, at least in
part, to the complexity of alcohol consumption in the human population. For
example, the impact of alcohol consumption/abuse on the lungs is often
confounded by comorbities (e.g., smoking) (121). Furthermore, it is possible that
alcohol consumption has a complicated dose response in the lung, vis-à-vis what
is observed in cardiovascular disease (i.e., hormesis) (121).
Rodent models of alcohol exposure to study the effects of alcohol on the
lung have been employed to compensate, at least in part, for the limitations of
the human consumption data. Common models include ethanol in drinking water,
acute (binge) ethanol intoxication, and chronic, ad libitum feeding of ethanol in
the Lieber-Decarli liquid diet. These animal models have been used to elucidate
many important mechanisms of pulmonary alcohol toxicity, including the
development of oxidative stress (4), the induction of transitional tissue
remodeling (4), and the sensitization of the lung to second injuries, (such as
lipopolysaccharide exposure (28, 104), burn injury (122), or infection (123)).
Alcohol consumption in most models is not sufficient to overtly change lung
tissue architecture, and thereby require a second ‘hit’. Specifically, rodent
aversion to alcohol-containing water/diet limits the blood alcohol concentrations
achievable in ad libitum models. By extension, these models serve as paradigms
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of low/moderate alcohol consumption and do not recapitulate end organ damage
associated with the drinking patterns of those with alcohol use disorders (124).
Aversion to alcohol is a well-known limitation of rodent models of alcohol
exposure, not only restricted to pulmonary models. Recently, a new model of
acute-on-chronic alcohol exposure was developed to study alcohol-induced liver
disease (80), in which chronic dietary exposure is followed by an acute bolus
gavage of alcohol. It is hypothesized that this model better recapitulates the
drinking patterns of an individual with an alcohol use disorder. Importantly,
hepatic pathology in this acute-on-chronic model is more similar to human
alcoholic liver disease. The impact of such an alcohol exposure regimen on lung
architecture and function has not been previously determined. Therefore, the
goal of this study was to examine lung injury and inflammation in a wellcharacterized experimental model of acute-on-chronic alcohol exposure.

B.

Experimental Procedures
1. Animals and Treatments
Animals were administered ethanol containing liquid diet or isocaloric

control liquid diet for 10 days, then a single binge of 5 g/kg ethanol or maltose
dextran as described in Chapter II Section A.3

2. Clinical Chemistry
Plasma transaminase activity (ALT and AST) were measured using
commercially available kits as described in Chapter II, Section C.1.
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3. Histology
Formalin-fixed paraffin-embedded liver and lung sections were stained
with hematoxylin and eosin and for CAE as described in Chapter II, Sections B.1
and B.3. BAL cells were stained as described in Chapter II, Section B.7.

4. RNA and real-time RT-PCR
Messenger RNA was isolated from tissue homogenate, and gene
expression of F4/80, CD68, Ly6g, CXCL1, CXCL2, CXCL15, and β-actin were
measured via real-time RT-PCR as described in Chapter II, Section D.

5. Pulmonary Mechanics Measurements
Pulmonary function was assessed in mice 24 hours after ethanol binge at
baseline and in response to inhaled methacholine as described in Chapter II,
Section E.

6. Statistical Analysis
Results are reported as means ± standard error mean (SEM; n= 4-6).
ANOVA with Bonferroni’s post-hoc test was used for determination of statistical
significance among treatment groups, using SigmaPlot (version 11.0). For
baseline pulmonary function measurements, a Student’s T-test was used to
determine significance between groups. For pulmonary function in response to
inhaled methacholine, statistical significance was determined using a two-way
repeated measures ANOVA. If necessary, transformation of data was used to
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achieve normally distributed data before ANOVA analysis. A p-value < 0.05 was
selected before the study as the level of significance. a, p < 0.05 compared to
pair-fed + maltose dextran binge, b, p < 0.05 compared to ethanol-fed + maltose
dextran binge.

C.

Results
1. Alcoholic steatohepatitis results from chronic + binge ethanol

exposure in mice.
Acute-on-chronic, or chronic + binge alcohol feeding produces alcoholic
steatohepatitis in mice (80). Therefore, to validate the model, indices of liver
injury and inflammation were measured in liver tissue 9 hours after oral gavage
of ethanol or isocaloric control (Figure 4.1A). Compared to animals receiving an
isocaloric control liquid diet and isocaloric control binge, animals fed an ethanol
containing liquid diet developed mild hepatic steatosis, as indicated by fatty
droplets in the liver tissue (Figure 4.1B, bottom left). Animals administered
ethanol binge after chronic ethanol feeding (Figure 4.1B, bottom right) developed
more pronounced alcoholic steatohepatitis, as indicated by fat accumulation and
the development of inflammatory foci (inset). This enhanced liver injury and
inflammation correlated with increased levels of plasma ALT and AST- markers
of liver injury. While ethanol feeding alone did not affect plasma ALT or AST,
chronic + binge ethanol exposure significantly increased ALT and AST levels, to
68 ± 7 and 81 ± 6 IU/L, respectively.
Chronic + binge ethanol feeding is known to cause immune cell infiltration
in the liver, predominantly characterized by neutrophil accumulation. Therefore,
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Figure 4.1. Effect of acute-on-chronic alcohol feeding on liver injury and
inflammation.
(A) Scheme of chronic + binge alcohol feeding. (B) Representative
photomicrographs of paraffin-embedded liver tissues stained with hematoxylin
and eosin (200×) and plasma alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) activity, 9 h post-binge. (C) Macrophage (F4/80 and
Cd68) and neutrophil (Ly6g) markers measured in liver tissue by qRT-PCR 9 h
post-binge
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markers of macrophages (F4/80 and Cd68) and neutrophils (Ly6g) were
measured in liver tissue 9 h post-binge using qRT-PCR (Figure 4.1C). Ethanol
feeding alone did not affect expression of any marker measured. However,
chronic + binge ethanol significantly decreased expression of F4/80 and Cd68 by
~50% of control (0.4 ± 0.1 and 0.5 ± 0.2 fold of control, respectively) but
significantly increased Ly6g expression by ~50% (1.5 ± 0.2 fold of control)
suggesting increased neutrophil infiltration.

2. Chronic + binge ethanol feeding produces mild neutrophilic

inflammation in the lung.
Although the effects of chronic + binge ethanol feeding have been wellcharacterized in the liver, the effects of this pattern of alcohol exposure on the
lung are unknown. Therefore, the effects of this pattern of ethanol exposure on
general lung morphology were characterized (Figure 4.2A, left). Neither ethanolcontaining liquid diet alone, nor chronic + binge administration caused any overt
pathological changes to the lung tissue, including the lung parenchyma and
major airways (not shown). However, an increase in lung tissue cellularity was
observed in lung tissue after chronic + binge alcohol exposure (Figure 4.2A, left).
To determine if this was due to inflammatory cell infiltration, lung tissues were
stained for chloracetate esterase (CAE), a relatively specific stain for neutrophils
(Figure 4.2A, right). Ten days of ethanol feeding alone did not cause any
significant neutrophil accumulation in the lung tissue; however, ethanol binge
after ethanol feeding caused a marked increase in neutrophil accumulation in
lung parenchymal tissue 9 h post-binge.
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Figure 4.2. Lung inflammation in chronic + binge ethanol-exposed mice.
(A) Representative photomicrographs of paraffin-embedded lung tissues
stained with hematoxylin and eosin (200×, left) and for chloroacetate esterase
(400×, right), 9 h post-binge. CAE-positive cells are stained bright pink. (B)
Macrophage (F4/80 and Cd68) and neutrophil (Ly6g) markers measured in
lung tissue by qRT-PCR 9 h post-binge. (C) Neutrophil chemokines, Cxcl1,
Cxcl2, and Cxcl15 were measured in lung tissue by qRT-PCR 9 h post-binge.
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To further characterize the influx of inflammatory cells into the lung tissue,
markers for macrophages and neutrophils were also measured in lung tissue via
qRT-PCR (Figure 4.2B). Neither ethanol feeding alone nor chronic + binge
ethanol exposure significantly affected expression of F4/80 or Cd68 in lung
tissue. However, similarly to the effects seen in liver tissue, chronic + binge
feeding significantly increased expression of the neutrophil marker Ly6g in lung
tissue by 2.8 ± 0.3 fold of control 9 h post-binge (Figure 4.2B).
To determine whether the influx of neutrophils into lung tissue was
mediated by neutrophil chemokines, the expression of Cxcl1, Cxcl22, and Cxcl15
was measured in lung tissue 9 h post-binge (Figure 4.2C). Compared to control,
animals administered 10 days of ethanol-containing liquid diet and ethanol diet
plus ethanol binge had significantly elevated pulmonary expression of Cxcl1 and
Cxcl2. In animals exposed to chronic + binge ethanol exposure, but not 10 days
of ethanol alone, expression of the lung-specific chemokine, Cxcl15, was
increased by ~50% (1.5 ± 0.1 fold of control) of control.

3. Inflammatory cells infiltrate the airways after chronic + binge ethanol

feeding.
To determine if the influx of neutrophils into the lung tissue was persistent,
the number and type of cells in the bronchoalveolar lavage fluid (BALF) 24 hours
after binge were examined. In control animals and animals fed ethanol-containing
liquid diet alone, the total number of cells recovered was similar at approximately
20,000 cells (23,428 ± 1407 and 18,666 ± 2942 cells, respectively). Additionally,
these cells were primarily macrophages (Figures 4.3A and 4.3B). However, the
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Figure 4.3. BAL cell accumulation after chronic + binge ethanol exposure.
(A) Total and differential counts of cells recovered (macrophages, neutrophils,
and lymphocytes) in bronchoalveolar lavage fluid. (B) Representative
photomicrographs (400x) of cytospins stained with Kwik-Diff differential
staining 24 h after binge.
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number of cells recovered in animals exposed to ethanol diet and ethanol binge
was significantly increased by approximately 2 fold (47,545 ± 8324 cells) (Figure
4.3A). This increase in total cell number was driven primarily by increased
neutrophils. Indeed, the total number of neutrophils (Figure 4.3B, arrows), as well
as the number of lymphocytes, was significantly increased in these animals while
the number of macrophages was unaffected (Figure 4.3A).

4. Chronic + binge alcohol exposure alters pulmonary mechanics:

airway hyper-responsiveness to methacholine.
To assess the impact of chronic + binge ethanol exposure on pulmonary
function, pulmonary mechanics were measured using the flexiVent system, as
described in Chapter II Section E, using the forced oscillation technique. Chronic
+ binge ethanol exposure had no significant effect on any variables measured at
baseline, including resistance (Rrs), compliance (C), pressure-volume loop
(Area), Newtonian resistance (Rn), tissue damping (G), or tissue elastance (H)
(Figure 4.4). However, animals exposed to chronic + binge ethanol feeding
demonstrated airway hyper-reactivity in response to the inhaled
bronchoconstrictive agent methacholine, as exhibited by significantly increased
airway resistance (Rrs) at 25 and 50 mg/mL methacholine, and increased
Newtonian Resistance, which is related to resistance in the central airways, at
the same doses (Figure 4.5). Compliance, tissue damping, and tissue elastance
were not significantly affected by chronic + binge ethanol exposure. Respiratory
resistance (i.e., the real part of respiratory system impedence) was significantly
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Figure 4.4: Effect of chronic + binge ethanol exposure on baseline
pulmonary mechanics.
Baseline pulmonary mechanics assessed 24 h post-binge using the forced
oscillation technique at a single perturbation frequency (2.5 Hz), or broadband
perturbation (1 to 20.5 Hz), and area of pressure-volume loops.
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Figure 4.5: Airway hyper-responsiveness to methacholine in chronic +
binge ethanol-exposed animals.
Airway reactivity to inhaled methacholine (0-50 mg/mL) assessed 24 h postbinge. Pulmonary mechanics were measured using the forced oscillation
technique at a single perturbation frequency (2.5 Hz), or broadband
perturbation (1 to 20.5 Hz).
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Figure 4.6: Effect of chronic + binge alcohol exposure on respiratory
resistance.
Respiratory resistance (the real part of respiratory system impedance) as a
function of frequency, measured 24 h post-binge in response to inhaled
methacholine (0 or 50 mg/mL).
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elevated at all frequencies measured, further indicating increased resistance in
the central airways (Figure 4.6).

5. Discussion

Alcohol consumption is well known to negatively impact the lung and to
increase the risk of upper respiratory tract infections and pneumonia (125, 126).
Furthermore, individuals with a history of an alcohol use disorder are more
susceptible to the development of ARDS, and often have a worse prognosis (19).
Importantly, all of these pulmonary complications of alcohol consumption appear
to be relegated to relatively heavy consumption. For example, the risk of ARDS
only increases dramatically in individuals who drink >3 drinks per day (127).
Likewise, the risk of pneumonia increases predominantly with heavy alcohol
consumption (126). There are still significant gaps in our understanding on the
mechanisms by which alcohol abuse mediates these effects on the pulmonary
system. Nevertheless, the prevailing hypothesis is that alcohol enhances injury
caused by a secondary insult (e.g., infection), rather than directly injuring the
lung, per se.
As mentioned in the Introduction, discovery of mechanisms of alcoholinduced organ damage has been hampered by a lack of relevant rodent models.
For example, Best et al. (73) incorrectly concluded that alcohol was not a direct
hepatotoxicant, based on studies of rodents consuming alcohol-containing
drinking water. Even with the development of liquid diets that increased daily
alcohol consumption (e.g., Lieber-DiCarli diet) (128), histologic changes to more
sensitive organs, such as the liver, did not recapitulate the human disease (124).
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This factor is likely due, at least in part, by a failure of these models to achieve
blood alcohol concentrations that are relevant to humans with an alcohol use
disorder (129, 130). For example, blood alcohol levels in mice on the chronic (6
week) Lieber-DeCarli liquid diet model typically reach maximally ~150 mg/dL
(80), and blood alcohol levels in mice on the ethanol in drinking water model are
typically lower (131). As mentioned previously, even though these relatively low
blood alcohol levels produce few pathologic changes in the lung, they do
sensitize the lung to further injury (104).
The purpose of the current study was to explore the impact of alcohol
exposure on lung histology and function in a newly developed model of chronic +
binge alcohol consumption. The rationale for this study is that the blood alcohol
contents (BACs) and alcohol exposure regimen may better recapitulate the
pattern of alcohol consumption observed in humans (124). In the United States,
the incidence of heavy binge drinking has significantly increased over the last 10
years, with currently 33% of adults reporting binge drinking in the last year.
Furthermore, individuals who heavily binge are more likely to go to the
emergency room with alcohol-related traumatic injuries (132). These statistics
speak to the need for a relevant animal model of heavy alcohol exposure for
these individuals at risk for ALI, such as the one used in the current study. As
has been shown previously, this model produced significant steatohepatitis, as
indicated histologically and by elevated plasma ALT and AST (Figure 4.1).
Interestingly, this ethanol exposure regimen increased recruitment of neutrophils
to the lung 9 hours after the ethanol binge (Figure 4.2); this pattern is similar to
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what is observed in the liver (Figure 4.1). Neutrophil recruitment 9 hours after
binge was associated with significant elevations in mRNA expression of the
chemokines Cxcl1, Cxcl2, and Cxcl15. This model also increased the total
number of cells collected in the BALF, driven primarily by an increase in the
number of BAL neutrophils (Figure 4.3). Finally, chronic + binge ethanol
exposure caused airway hyper-responsiveness to methacholine, indicative of
increased resistance in the central airways (Figures 4.5-6).
Previous studies have shown that alcohol exposure is sufficient to produce
pathologic changes to the lung, including ECM remodeling, oxidative stress and
alveolar macrophage dysfunction (4, 43). However, these changes have
previously been considered insufficient to directly cause histologic damage to the
lung. Moreover, few (if any) studies have shown that ethanol exposure alone will
directly induce an inflammatory response in the lung. Indeed, a similar absence
of pathology was observed here when dietary ethanol was given alone (i.e.,
without the binge). The finding in the current study that ethanol exposure is
sufficient to cause a marked increase in inflammatory cell recruitment to the lung
and into the BALF is therefore novel.
Although chronic + binge ethanol feeding caused influx of inflammatory
cells into the lung tissue and BAL, this inflammation was relatively mild. The
functional consequences of these changes were therefore unclear. Indeed, due
to the “interdependent” nature of the lung parenchyma and central airways,
inflammatory damage to the parenchyma may manifest as resistance in the
central airways, and vice-versa (133). This ethanol exposure regimen did not

87

impact any basal index of airway function, as determined by pulmonary
mechanics assessment (Figure 4.4); however, it did increase airway resistance
(Rrs) and Newtonian resistance (Rn) in response to methacholine (Figure 4.4).
These data, combined with an upward shift in Rrs over increasing frequency (the
real part of respiratory impedence), indicate increased resistance in both the
central airway and lung parenchyma in response to an exogenous stimulus.
These effects of alcohol exposure on pulmonary function are novel in an
experimental model. However, they are not without precedence in human
alcohol exposure studies. For example, airway hyper-responsiveness or
“alcohol-induced asthma” has been demonstrated in humans; this phenomenon
is hypothesized to be potentially the result of acetaldehyde toxicity and/or of
impurities in the beverage (121, 134, 135). In contrast, others have shown that
ethanol can cause bronchodilation in humans (136, 137) and it was used
historically as a rescue therapy for asthma. The underlying causes of these
apparent differing responses are unclear; however, alcohol dose may be critical.
Furthermore, most studies have investigated the effect of concomitant alcohol
exposure on lung hyper-responsiveness (138). In contrast, the impact of ethanol
pre-exposure on stimulated lung mechanics, such as performed here, has not
been tested. Several studies in lung and in other organs have demonstrated that
alcohol has differing, even contradictory, responses depending on the timing of
the exposure. Nevertheless, the development of this mouse model yields a new
tool to directly determine impacts and mechanisms of alcohol on lung mechanics.
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In conclusion, current mouse models of alcohol exposure have not
previously been shown to cause overt inflammatory changes in the lung. One
common limitation of ad libitum ethanol exposure models (e.g., ethanol in
drinking water or chronic Lieber-DeCarli liquid diet) is their inability to sufficiently
recapitulate risky human drinking patterns, as well as pathology on sensitive
target organs, such as the liver. This liver pathology may be an important feature
for reproducing the disease state of alcoholic patients at risk for developing
ARDS. In fact, mortality in ARDS is almost 100% in patients with end-stage liver
disease. The newly developed chronic + binge model of alcohol exposure more
accurately reproduces risky drinking patterns in alcoholic patients, who are most
at risk for developing sepsis-induced ARDS. The current study provides novel
findings that this pattern of alcohol exposure, in the absence of any secondary
inflammatory insult, caused mild neutrophilic inflammation 9 and 24 hours after
ethanol binge, as well as exacerbated central airway resistance after
methacholine inhalation. This animal model may be useful, and potentially more
relevant, for identifying mechanisms by which alcohol abuse sensitizes at-risk
individuals to ALI and ARDS.

89

CHAPTER V

ASSESSING THE ROLE OF HEPATIC-DERIVED CYTOKINES IN ALCOHOLENHANCED ALI; A NOVEL, NANOPARTICLE-BASED APPROACH TO
SELECTIVELY GENETICALLY MODIFY HEPATIC MACROPHAGES

A.

Introduction
Human diseases are generally multi-stage, multi-hit processes; it is

therefore not surprising that multiple cells within a target organ contribute to
disease pathology. The potential contribution of signals outside the target organ
to disease pathology is also a well-accepted concept. However, experimental
validation of these concepts has been technically difficult in some cases. The
advance of temporal and/or locational control of gene expression (e.g., with
conditional transgenics) has further enabled research to be performed on a
system level. These advances coevolved with the era of ‘omics research in
which large amounts of data can be simultaneously analyzed for trends and
effects. The net result is that system level analyses of disease, and organ-organ
interactions are gaining attention of the research community. Mechanistic
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understanding of some of these inter-organ interactions is subsequently very
strong [e.g., the ‘gut-liver axis’ (139)].
Although less well-characterized, several studies indicate
interdependence between liver and lung, potentially via mediators released from
the gut. For example, mortality in ARDS patients with hepatic failure is almost
100% (140). Furthermore, pulmonary injury induced by systemic endotoxin can
be altered by mediators released from the liver (e.g., TNFα) (141, 142). In an
elegant study, Siore et al. (85) demonstrated that LPS-induced lung damage
requires perfusion through the liver. Recently, depletion of systemic TNFα
(etanercept) was demonstrated to prevent pulmonary injury in a mouse model of
alcohol-enhanced ALI (35). However, while experimental data indicate that the
liver is a major source of circulating TNFα after LPS administration, blocking
systemic TNFα using drugs such as etanercept does not directly address the
hypothesis that hepatic-derived cytokines drive injury in distal organs, such as
the lungs (Figure 5.1A).
To more empirically ascertain the role of hepatic-derived cytokines in
injury in other organs, including the lung, a liver-specific, targeted approach must
be developed. Several “liver-specific” knockout animal models have been
established using Cre-lox technology, in which the bacterial enzyme Cre
(cyclization recombinase) excises a gene of interest flanked by loxp (locus of Xover in P1) sites. Cre recombinase can be engineered to be driven by specific
promoters to target various cell types in the liver, such as the albumin-Cre mouse
to target hepatocytes and the lecithin-retinol acyltransferase (Lrat)-Cre mouse,
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among others, to target hepatic stellate cells (143). However, hepatic
macrophages, Kupffer cells, are the primary source of cytokines, including TNFα
in the setting of inflammatory injury. Therefore, these available liver-specific
knockout mice will be insufficient to target expression of hepatic-derived
cytokines. To date, the most “selective” genetic approaches available to target
Kupffer cells target cells of the myeloid lineage, including M lysosome (LysM-Cre
mouse) and colony stimulating factor-1 receptor (CSF1R-Cre mouse). These
approaches would induce Cre-mediated excision, therefore, in all macrophage
populations. There are more traditional approaches available to ablate Kupffer
cells, such as administration of gadolinium chloride or liposome-encapsulated
chlodronate. However, these compounds only serve to eliminate macrophages,
and therefore do not allow for investigation of specific macrophage-derived
mediators. Moreover, these approaches are not entirely selective to liver
macrophages. For example, intravenous administration of chlodronate liposomes
also targets a wide variety of macrophage populations, and is not specific to the
liver (144). Taken together, these limitations highlight the need for a selective,
inducible, transgenic approach.
A second variety of Cre recombinase is that which can be temporally
induced by drugs. For example, the estrogen receptor agonist, tamoxifen, can be
used to induce Cre expression. The commercially available R26CreER mouse
utilizes an endogenous, tamoxifen-inducible promotor, Gt(ROSA)26Sor, that will,
upon activation, express Cre in any cell that has been targeted by tamoxifen.
Therefore, it is hypothesized that liver-targeted delivery of tamoxifen may be
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sufficient to induce selective Cre-mediated excision in Kupffer cells. To achieve
this targeted delivery, a nanoparticle-based approach may be utilized. Poly
(lactic-co-glycolic acid) (PLGA) nanoparticles are non-toxic, biodegradable
nanoparticles which, in their unmodified state, have been shown to accumulate in
the liver with a majority of particles accumulating in Kupffer cells (89). The goal of
the study presented in this chapter is therefore to determine if tamoxifen-loaded
PLGA nanoparticles may be utilized to selectively induce Cre-mediated excision
in the liver, while avoiding other macrophage populations such as those in the
lung. Development of such an inducible transgenic system would be useful for
determining the role of hepatic-derived cytokines in propagating injury in other
organs.

B.

Experimental Procedures
1. Generation of transgenic animal lines
R26CreER/mTmG mice were generated as described in Chapter II

2. Animals and treatments
Mice were injected intraperitoneally with tamoxifen, or injected
intravenously or intrasplenically with tamoxifen-loaded PLGA nanoparticles as
described in Chapter II, Sections 5, 6, and 7, respectively. Tissues were collected
upon sacrifice as described in Chapter II.
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3. Synthesis of PLGA nanoparticles
Nanoparticles were synthesized as described in Chapter II Section F.

4. Characterization of PLGA nanoparticles
PLGA nanoparticles were characterized as described in Chapter II Section
G.

5. Imaging of native fluorescence
Tissues were fixed and native fluorescence of tdTomato and eGFP were
imaged in liver and lung sections as described in Chapter II, Section B.6.

6. Histology
Immunohistochemistry for GFP was performed in formalin-fixed, paraffinembedded liver and lung sections as described in Chapter II Section B.4

7. RNA isolation and qRT-PCR
RNA was isolated from liver, lung, kidney, and spleen homogenates and
reverse transcribed as described in Chapter II. Messenger RNA expression of
select genes was measured via qRT-PCR as described in Chapter II.

8. Statistical analysis
Statistical significance was determined as described in Chapter II, Section
H. a, p < 0.05 compared to vehicle control.
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Figure 5.1: Proposal to utilize transgenic reporter mouse model to
investigate interactions between the liver and lung.
(A) In the setting of inflammatory injury (e.g., intraperitoneal LPS), the liver and
lung may be directly damaged. However, hepatic-derived mediators, such as
TNFα, may contribute to injury in the lung. (B). Scheme of tamoxifen-inducible
Cre-mediated excision of the mT/mG reporter construct.
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Figure 5.2: Intraperitoneal administration of tamoxifen successfully
induces complete Cre-mediated excision of red fluorescence and
expression of green fluorescent protein.
Representative photomicrographs (200x) of native red fluorescence (top
panels) and green fluorescence (middle panels) counterstained with DAPI
(blue) in frozen liver tissues after i.p. administration of tamoxifen (right) or corn
oil vehicle (left) as described in Materials and Methods. Merged images are
shown in bottom panels.
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C.

Results
1. Validation of the R26CreER+/mTmG+ mouse strain.
As mentioned in the Introduction, the goal of the current study was to

design and characterize a transgenic animal model to selectively genetically alter
hepatic resident macrophages (Kupffer cells) without transducing alveolar
macrophages. A previously-established reporter mouse strain, known as the
mT/mG mouse, was utilized to test this hypothesis. Prior to Cre-mediated
recombination, this mouse ubiquitously expresses red fluorescent membranetargeted tandem dimer Tomato (mT) driven by a chicken β-actin core promotor
with CMV enhancer (pCA). In the presence of Cre recombinase, flox-flanked mT
is excised, and the mice express membrane-targeted enhanced green
fluorescent protein (mG) (Figure 5.1B). As discussed in Chapter II (Experimental
Procedures), these mice were crossed with tamoxifen-inducible Cre recombinase
(R26CreER). When injected intraperitoneally with vehicle (corn oil) tissues
ubiquitously express mT (red fluorescence), as demonstrated by imaging native
fluorescence in liver tissues. After i.p. tamoxifen injection, red fluorescence is
diminished, and all cells express mG (green fluorescence) (Figure 5.2).

2. Characterization of tamoxifen-loaded PLGA nanoparticles.
PLGA nanoparticles had an average diameter of 178 ± 34 nm, and
demonstrated smooth and spherical morphologies (Figure 5.3A). PLGA
nanoparticles encapsulated 144.6 ± 18 µg tamoxifen per mg of nanoparticles,
corresponding to an encapsulation efficiency of 72%. The total cumulative
release of tamoxifen from PLGA NPs was measured over 1 week (Figure 5.3B
99

Figure 5.3: Characterization of tamoxifen-loaded PLGA nanoparticles.
(A) Scanning electron microscopy (SEM) image of PLGA nanoparticles. Scale
bar represents 1 µM. (B) Cumulative release of tamoxifen from nanoparticles
over one week as µg of tamoxifen released per mg of nanoparticles and (C) as
the percent of total tamoxifen loaded.
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and 5.3C). Release of tamoxifen was relatively low, with less than 20% of loaded
tamoxifen released into solution after 1 week.

3. Intravenous administration of tamoxifen-loaded PLGA NP fails to
selectively transduce liver cells.
It is proposed that tamoxifen-loaded PLGA nanoparticles could be utilized
to selectively activate tamoxifen-inducible Cre in the liver, thereby causing liverspecific excision of the mT/mG reporter construct. One potential route of
administration was intravenous (tail vein) injection. Tamoxifen-loaded
nanoparticles (1.5 mg nanoparticles per 25 g mouse) or vehicle (saline) were
administered i.v., and fixed tissues were collected for frozen sectioning and
imaging 7 days later, as described in Chapter II (Experimental Procedures).
Compared to vehicle control, i.v. nanoparticle administration robustly induced
expression of mG in the liver (Figure 5.4A), though not as robustly as i.p.
tamoxifen administration (Figure 5.2). However, Cre-mediated excision was not
liver-specific. For example, Figure 5.4B illustrates that Cre-mediated excision and
subsequent mG expression was also seen in the lung compared to vehicle
control.

4. Intrasplenic injection of tamoxifen-loaded PLGA nanoparticles
selectively induces expression of mG in the liver.
Previous studies have reported that PLGA nanoparticles accumulate in
the liver after intrasplenic injection, with a high percentage of injected
nanoparticles accumulating in Kupffer cells (89). Therefore, tamoxifen-loaded
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Figure 5.4: Native green fluorescence in liver and lung after i.v.
administration of tamoxifen-loaded PLGA nanoparticles.
(A) Representative photomicrographs (200x) of native red (left) and green
(middle) fluorescence in liver sections after i.v. administration of vehicle
(saline) or 1.5 mg tamoxifen-loaded PLGA nanoparticles. (B) Representative
photomicrographs (200x) of native red (left) and green (middle) fluorescence
counterstained with DAPI in lung sections after i.v. administration of vehicle
(saline) or 1.5 mg tamoxifen-loaded PLGA nanoparticles. Merged images are
shown in the right column.
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PLGA nanoparticles were injected at increasing concentrations (0-1.5 g/mouse)
intrasplenically in R26CreER+/mTmG+ mice. Membrane-targeted eGFP was
detected immunohistochemically in the liver and lung (Figure 5.5). Some cases
of spontaneous mG expression was observed in animals receiving vehicle
(saline) alone in both the liver and lung (Figure 5.5, top panels). In the liver,
intrasplenic injection of nanoparticles produced a dose-dependent increase in
GFP staining (Figure 5.5, right panels). GFP staining appeared in both
hepatocytes and non-parenchymal cells. There was no observable effect of
nanoparticle injection on GFP staining in the lung (Figure 5.5, left panels).
To quantify mG expression in various tissues, mRNA expression of Egfp
was measured by qRT-PCR (Figure 5.6A). In lung, kidney, and spleen tissue
homogenates, Egfp expression was unaffected by tamoxifen NP injection.
Alternatively, in the liver, Egfp expression was significantly induced
approximately 2 fold after 0.75 mg tamoxifen NPs, and induced ~10 fold at the
highest dose of tamoxifen NP. To further confirm tamoxifen-mediated excision,
native fluorescence of mT (red fluorescence) and mG (green fluorescence) was
detected in frozen liver and lung sections (Figure 5.6B). In the lung, red
fluorescence was observed ubiquitously with no detectable green fluorescence.
In the liver, red fluorescence also predominated, however, clear green
fluorescence was also observed throughout the tissue.

105

Figure 5.5: Membrane-targeted eGFP expression after intrasplenic
injection of tamoxifen-loaded PLGA nanoparticles in liver and lung.
Representative

photomicrographs

(200x)

of

eGFP

detected

immunohistochemically after intrasplenic administration of tamoxifen-loaded
PLGA nanoparticles (0.375, 0.75, or 1.5 mg per 25 g mouse) or vehicle (saline)
in formalin-fixed, paraffin-embedded lung and liver sections
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Figure 5.6: Enhanced-GFP expression in liver, lung, kidney, and spleen
following

intrasplenic

administration

of

tamoxifen-loaded

PLGA

nanoparticles.
(A) mRNA expression of Egfp measured via qRT-PCR in liver, lung, kidney and
spleen tissue homogenates of animals injected intrasplenically with 0, 0.375,
0.75, or 1.5 mg tamoxifen-loaded PLGA nanoparticles. (B) Representative
photomicrographs (200x) of native red and green fluorescence in frozen liver
and lung sections following intrasplenic administration of 0.75 mg tamoxifenloaded PLGA nanoparticles.
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D.

Discussion
The goal of this study was to develop an in-vivo system to determine the

role of hepatic-derived mediators, such as cytokines and chemokines, in
propagating injury in other organs. Interactions between the liver and other
organs have been well-characterized in certain disease models, e.g., the “gutliver axis” in alcoholic liver disease. Current approaches used to target the liver
are limited in specificity (the cell population they target) and the persistence of
the effect. For example, liver-specific Cre-lox approaches, such as albumindriven Cre, target only hepatocytes and are therefore insufficient to interrogate
the role of Kupffer cells- the hepatic cell type which produces a majority of
inflammatory meditators. Other methods to target the liver, such as viral vectors
(e.g., rAd and rAAV), are limited by poor transduction efficacy (rAAV) or relatively
brief transduction (rAd). Methods to selectively target Kupffer cells (versus other
hepatic cells) include transgenic approaches, including LysM-Cre transgenics
and ‘Kupffer cell chimeras’ have also been developed. Although these methods
are relatively selective for hepatic macrophages versus other hepatic cell types,
both tend to target extrahepatic macrophages. Therefore, the current study
sought to develop a targeted transgenic approach to selectively modify the
genetics of hepatic macrophages while avoiding macrophage populations in
other tissues, such as the lung.
To achieve this goal, a double transgenic (i.e., Cre-LOX) approach was
employed, wherein Cre induction was controlled by an external stimulus
(R26CreER+/mTmG+). In this strain, systemic tamoxifen administration will
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transduce nearly every cell in the organism (Figure 5.2). Restriction of the
induction of Cre was facilitated by selective delivery of tamoxifen to the target
cells with nanoparticles. The liver in general, and Kupffer cells in particular, are
well known targets of injected nanoparticles. Indeed, several of the modifications
to the current generation of nanoparticles are designed to avoid the RES and the
liver (145). Thus, nanoparticles employed in this study were ‘reverse engineered’
to accomplish exactly the opposite goal.
Based on this previously published work, it was expected that i.v. injection
of nanoparticles would accumulate in the liver and thereby selectively transduce
that organ. It was therefore initially somewhat surprising that i.v. injection of
nanoparticles, although effective at transducing the liver, also had off-target
effects in other organs (e.g., lungs; Figure 5.4). These data may not be mutually
exclusive with previous findings; the lungs are the first capillary bed that an
intravenous agent contacts. Furthermore, final accumulation of nanoparticles
determined in previous work may differ from sites wherein the particles
accumulate at least transiently. Nevertheless, a more liver-specific delivery
method was developed employing intrasplenic injections. Previous work has
shown that PLGA nanoparticles, when injected intrasplenically, accumulate in
Kupffer cells (89). Indeed, intrasplenic injection of tamoxifen-loaded PLGA
nanoparticles induces dose-dependent expression of Egfp in the liver, but did not
induce expression in the lung, kidney, or spleen (Figures 5.5 and 5.6).
Interestingly, both hepatocytes and Kupffer cells were transduced.
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The implications of these results are far-reaching. First, these
experiments have developed a tool to discern the specific role of liver-derived
cytokines in injury in other organs. Although hepatocyte-specific promoters exist,
many cytokines are derived from the resident hepatic macrophages, the Kupffer
cells. To date, no Kupffer cell-specific promotor has been identified that selects
for this cell type over macrophages in other tissues. Furthermore, liver-derived
products may be sourced from several hepatic cell types. For example, the
release of TNFα into the systemic circulation is controlled by TNFα converting
enzyme (TACE), which is derived from both hepatocytes and Kupffer cells. To
study the role of hepatic TNFα on extrahepatic injury, a flox-flanked TACE
(TACEflox ) mouse could be employed. Selective deletion of this enzyme could, in
theory, prevent the release of TNFα from the liver into systemic circulation while
not affecting local, paracrine effects of TNFα in the liver. Systemic TNFα is
proposed to contribute to injury in the lung (35) and brain (146), among others,
and cytokines that may be of hepatic origin have been implicated in multiple
organ failure in a variety of disease states, including decompensated liver
disease, systemic inflammatory response syndrome (SIRS) (82), and acute
pancreatitis (147). The system described here would be useful for determining
the specific origin of cytokines of interest. Finally, the development of this tool
has implications beyond the scope of basic research. Clinically, identifying the
role of hepatic-derived cytokines in disease in other organs provides novel insight
for the treatment of these conditions. For example, these data provide support for
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identifying underlying liver disease as a screening and/or treatment goal in
patients at risk for developing multiple organ failure.
This approach, however, is not without limitation. First, this approach
requires intrasplenic administration of nanoparticles, and therefore requires
moderate technical skill to perform the necessary surgical procedure. Next,
although it was histologically observed that Cre-mediated mG expression was
robustly induced in Kupffer cells, mG expression was also noted in hepatocytes
and possibly other non-parenchymal cells. The current approach will therefore
not be sufficient to specifically target Kupffer cells while avoiding other hepatic
cell types. This limitation, however, may actually be advantageous in some
scenarios. Additionally, this approach could be more selective by employing a
Kupffer-cell specific promotor to drive expression of Cre. Indeed, the C-type
lectin CLEC4F has been characterized as a Kupffer cell-specific gene (148).
However, no commercially available Cre-expressing mouse driven by this
promotor is currently available. Third, this model does not address the possibility
that communication between the liver and other organs may be bi-directional.
Indeed, in experimental studies of ventilator-induced ALI, data suggests
mediators released from the lung may damage tissues in other organs, including
the liver (149, 150). However, the dose and route of administration of
nanoparticles could be easily altered to target macrophage populations in other
tissues. For example, direct administration of nanoparticles to the lung (e.g.,
intratracheal instillation or oropharyngeal aspiration) would likely selectively
target alveolar macrophages, while avoiding hepatic macrophages. Finally, the
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current system will only address the role of inflammatory mediators released from
the cells that are residing in the liver at the time of intrasplenic nanoparticle
injection. As such, inflammatory cells recruited to the liver at any point in the
disease model after nanoparticle administration will likely be unaffected. This
limitation, however, may also be a strength because it allows for separation of
the effects of resident versus recruited macrophages on systemic release of
inflammatory mediators.
In conclusion, the findings presented here describe a novel, in-vivo
approach to selectively edit the genetics of hepatic cells, including hepatocytes
and Kupffer cells. Using animals expressing tamoxifen-inducible Cre
recombinase, any flox-flanked gene of interest may be excised following targeted
delivery of the inducing agent. This system has potential applications for
research in any disease state in which hepatic-derived cytokines or other
signaling molecules are implicated, such as alcohol-enhanced ALI or shockinduced multiple organ failure. Such studies may provide new insight for the role
of underlying liver injury or inflammation in the diagnosis and treatment of
disease in other organs.
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CHAPTER VI

DISCUSSION AND CONCLUSIONS

A.

Restatement of goals and questions
The overall goal of the work described in this dissertation was to expand

on the unifying hypothesis that not only do the liver and lung share parallel
mechanisms of injury in response to alcohol exposure, but that injury in these two
systems may be interdependent. The Arteel group has demonstrated that PAI-1
and fibrin ECM deposition are critical in alcohol-induced liver injury. The
experiments in Chapter III were performed to determine the role of this
mechanism of injury in alcohol-enhanced endotoxemia-induced ALI, thereby
identifying potential parallel mechanisms of injury in the liver and lung. Chapter
IV characterized lung injury and inflammation in a model of acute-on-chronic
alcohol exposure originally developed to study alcoholic liver disease, thereby
laying the groundwork for further exploring parallel mechanisms of injury. Finally,
Chapter V describes the development of an inducible transgenic animal model to
selectively alter the genetics of hepatic macrophages to test the hypothesis that
hepatic-derived mediators may contribute to lung injury. Taken together, these
studies provide new insight into the complex mechanisms of alcohol-related
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acute lung injury by building on well-described mechanisms of liver injury, and
also develop a novel transgenic animal model to explore the communication
between these two organs.

B.

Major findings of this dissertation
1. PAI-1-mediated fibrin accumulation and platelet aggregation play a
critical role in alcohol-enhanced experimental ALI.
Previous studies from the Arteel group have demonstrated that PAI-1

plays a critical role in alcohol-induced liver injury. Genetic deletion of PAI-1
protected against alcohol-induced inflammation and necrosis in a model of
chronic enteral ethanol administration in mice, as well as in LPS-induced liver
injury after acute ethanol exposure. Additionally, PAI-1 has been shown to be
involved in the development of LPS-induced acute lung injury, as well as other
forms of lung injury, such as bleomycin-induced pulmonary fibrosis. However, the
role of PAI-1 in alcohol-enhanced ALI has not been previously determined. The
goals of Chapter III were three-fold: 1) to establish if PAI-1 and its downstream
targets are up-regulated in alcohol-enhanced acute lung injury, 2) to determine
the role of PAI-1 in injury and inflammation in this disease state and 3) to
establish a potential mechanism by which PAI-1 and its downstream targets
contribute to alcohol-enhanced ALI.
First, to investigate this potential parallel mechanism of liver and lung
injury, PAI-1 expression and fibrin accumulation were measured in the lung
tissue of animals receiving LPS injection with chronic ethanol pre-exposure (a
previously established model of alcohol-enhanced ALI) (35). The studies in
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Chapter III determined that, in fact, chronic ethanol pre-exposure exacerbated
Pai-1 mRNA induction and protein expression after LPS administration. As
discussed in detail in Chapter I Section A.5, induction of PAI-1 impairs fibrin
degradation by inhibiting plasmin. The Arteel group has previously demonstrated
that blocking fibrin accumulation in the liver by knocking out PAI-1 or inhibiting
thrombin cleavage protected against alcohol-enhanced inflammation (38).
Therefore, fibrin accumulation in the lung was also assessed. Similar to the
phenomena observed in the liver, chronic ethanol pre-exposure exacerbated
fibrin accumulation in the lung tissue.
Fibrin can accumulate in a tissue as a result of enhanced activation of the
coagulation cascade (thrombin cleavage) or by impaired fibrin degradation (PAI-1
induction). In addition to the enhanced PAI-1 induction seen in the lung tissue in
Chapter III, ethanol pre-exposure was also associated with enhanced thrombin
activation. These data suggest that in this experimental setting, fibrin
accumulation in the lung is promoted on “both sides” of the coagulation cascade,
i.e., by both enhanced generation and impaired degradation. Fibrin matrices can
be pro-inflammatory by a number of mechanisms, as discussed in Chapter I,
Section A.5. One such mechanism is by acting as a substrate for the adhesion
of inflammatory cells, including platelets. In Chapter III, LPS administration, both
alone and with alcohol pre-exposure, caused accumulation of platelets in the
lung. Next, the causal role of PAI-1 induction on fibrin deposits and platelet
accumulation was determined using PAI-1-deficient mice. As expected, PAI-1
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deletion attenuated pulmonary fibrin deposition. Interestingly, the loss of fibrin
was associated with complete mitigation of platelet accumulation.
The second goal of this study was to determine the role of PAI-1 and its
downstream targets in injury and inflammation in alcohol-enhanced ALI. To this
end, lung injury and inflammation were assessed in ethanol and/or LPS-treated
wild-type or PAI-1 knockout mice. As expected, ethanol pre-exposure
exacerbated endotoxemia-induced ALI in wild-type mice. Interestingly, in a
finding similar to that of previous studies in the liver, PAI-1-deficient animals were
protected against alcohol-enhanced edematous lung injury. Alcohol-enhanced
alveolar septal thickening and BAL total protein levels were completely
attenuated in mice lacking PAI-1. Interestingly, pulmonary neutrophil
accumulation was unaffected by ethanol pre-exposure or PAI-1 deficiency,
despite the effects of these variables on the measurements of injury assessed in
this model.
Finally, the experiments in Chapter III were performed to suggest a
proposed mechanism by which PAI-1 and its downstream targets are involved in
alcohol-enhanced ALI. Even though the number of neutrophils was unaffected
by diet or genotype, the activation state of these inflammatory cells may be
altered by exposure to different cytokines and chemokines. Additionally,
cytokines and chemokines themselves may also promote tissue damage (105).
Therefore, mRNA expression of cytokines, chemokines, and vascular adhesion
molecules was measured. PAI-1 deficiency attenuated the ethanol-enhanced
expression of the chemokines MIP-2 (Cxcl2) and KC (Cxcl1), as well as the
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vascular adhesion molecules Icam-1 and V-cam1. Platelet-mediated signaling
events can lead to expression of these chemokines upon aggregation and
activation, and, interestingly, Chapter III illustrated that PAI-1 deficiency almost
completely blocks LPS-induced platelet accumulation in the lung. Therefore,
expression of MIP-2 and KC was measured in lung tissue of mice lacking integrin
β3, the beta subunit of the platelet specific integrin αIIBβ3, a primary integrin
receptor by which platelets adhere to fibrin matrices. Interestingly in β3 knockout
animals, ethanol-enhanced MIP-2 and KC expression was significantly blunted to
levels similar to LPS administration alone, similar to what was seen in PAI-1deficient animals. Interestingly, ethanol-enhanced PAI-1 expression was also
attenuated in these β3 knockout animals. Taken together, these results indicate
that the mechanism whereby alcohol exaggerates LPS-induced lung injury
requires PAI-1-mediated pulmonary fibrin accumulation, and suggest a novel
mechanism whereby alcohol contributes to inflammatory ALI by enhancing
fibrinogen-platelet engagement.
Text Box 6.1

Take-home points


Alcohol pre-exposure exacerbates PAI-1 induction and fibrin
deposition in the lung. LPS injection causes pulmonary platelet
accumulation.



Knocking out PAI-1 almost completely attenuated fibrin and platelet
accumulation. Furthermore, these PAI-1-deficient mice were protected
against alcohol-enhanced ALI.



Blocking PAI-1-mediated fibrin accumulation, as well as platelet
adherence to fibrin (β3 knockout animals), mitigated chemokine
expression in the lung, suggesting a possible novel mechanism of
alcohol-enhanced ALI.
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2. Chronic + Binge alcohol exposure promotes inflammation in the lung
and alters pulmonary function.
As described in the Chapter I Section 6, a major limitation of in vivo
studies investigating the toxic effects of alcohol on the lung is the mouse models
which are often employed. Indeed, ad libitum ethanol exposure models, including
ethanol in drinking water and chronic Lieber-DeCarli liquid diet produce relatively
low blood alcohol levels and mild, if any, clinically relevant liver pathology.
Recently, a new model of acute-on-chronic alcohol exposure was developed to
study alcohol-induced liver disease (80), in which chronic dietary exposure is
followed by an acute bolus gavage of alcohol. It is hypothesized that this model
better recapitulates the drinking patterns of an individual with an alcohol use
disorder. Importantly, hepatic pathology in this acute-on-chronic model is more
similar to human alcoholic liver disease. The experiments described in Chapter
IV characterize the previously uninvestigated effects of this alcohol exposure
regimen in the lung. As such, the goals of the experiments in Chapter IV were to
1) characterize lung injury and/or inflammation in this new, perhaps more
relevant model of alcohol exposure, 2) to determine what, if any, functional
effects this ethanol exposure pattern has on pulmonary function, thereby 3)
determining if alcohol exposure alone, absent any secondary injury, is sufficient
to cause pulmonary inflammation or injury.
Liver injury and inflammation in the acute-on-chronic, or chronic + binge,
has been previously well-characterized as resembling alcoholic steatohepatitis,
with fat accumulation, inflammation, and necrosis. These findings were
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recapitulated in Chapter IV. While mice administered 10 days of ethanolcontaining liquid diet alone showed little liver pathology, as seen histologically or
biochemically, 10 days of alcohol feeding followed by ethanol binge (chronic +
binge ethanol) dramatically exacerbated liver injury and inflammation. As
previously characterized, this inflammation was predominately neutrophilic in
nature, more closely resembling the human pathology. The effects of chronic +
binge ethanol exposure have been uncharacterized in the lung, and the first goal
of this study was to address this question. Similar to what is seen in the liver, 10
days of ethanol-containing liquid diet produced no overt pathologic effects in the
lung, i.e., no inflammatory cell recruitment or alterations in tissue architecture.
Alternatively, chronic + binge ethanol exposure promoted recruitment of
neutrophils, which were seen sequestered in the lung parenchyma 9 hours after
ethanol binge. This neutrophil recruitment was associated with significant
induction of the neutrophil chemokines Cxcl1, Cxcl2, and Cxcl15. This
inflammation was persistent. Indeed, although 24 hours after ethanol binge, the
neutrophil infiltration in the lung tissue had decreased (data not shown), the
number of cells recovered in the BALF was significantly elevated. This increase
in total BAL cells was driven primarily by an increase in neutrophils. Indeed, the
total number of BAL neutrophils was significantly elevated in mice exposed to
chronic + binge ethanol. The total number of lymphocytes was also significantly
elevated in this group, although to a lesser extent.
Population studies have indicated that alcohol consumption may trigger
asthma attacks in some individuals (135). However, data from experimental in-
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vivo studies are unclear, and at times conflicting. Therefore, in accordance with
the second goal of this study, the effect of chronic + binge alcohol exposure on
pulmonary mechanics were measured. At baseline, ethanol exposure did not
affect pulmonary mechanics. However, alcohol exposure caused airway
hyperreactivity in response to inhaled methacholine, as demonstrated by
increased airway resistance, Newtonian resistance, and respiratory resistance
(the real part of respiratory impedence). These data suggest that acute-onchronic alcohol exposure promotes hyperreactivity, likely in both the central
airways and lung parenchyma. Taken together, these data address the third goal
of this study- to determine if ethanol alone is sufficient to cause inflammation in
the lung. The results of this study suggest that chronic + binge ethanol alone
causes pulmonary inflammation and affects pulmonary mechanics.
Text Box 6.2

Take-home points


Chronic + binge alcohol exposure causes inflammation in the lung,
marked by neutrophil infiltration in the lung tissue and BALF



Airway resistance in response to inhaled methacholine is increased in
animals exposed to chronic + binge alcohol



Taken together, these data suggest that, based on dose and pattern
of exposure, alcohol alone is sufficient to cause inflammation in the
lung and alter pulmonary mechanics.
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3. Intrasplenic administration of tamoxifen-loaded PLGA nanoparticles
selectively induces cre-mediated recombination in the liver.
Multiple organ failure is highly recognized as a hallmark of end-stage
alcoholic liver disease. However, the role of organ-organ crosstalk in the early
stages of disease is increasingly appreciated. In fact, studies have suggested
that extra-thoracic cytokines, like TNFα, may contribute to alcohol-enhanced ALI.
However, no experimental system is currently available to test this hypothesis.
The goals of Chapter V of this dissertation were therefore 1) to identify a drug
delivery method which selectively targets the liver versus the lung and 2) to
develop a transgenic animal to demonstrate the feasibility of selectively inducing
a transgene in the liver versus the lung.
To address the first goal, this study used tamoxifen-loaded PLGA
nanoparticles and a dual-fluorescence reporter mouse to attempt to develop this
tool. The mT/mG reporter construct expresses red fluorescent, membranetargeted TdTomato (mT) before Cre-mediated excision. Upon induction of Cre,
flox-flanked mT is deleted and membrane-targeted enhanced GFP (mG) is
expressed. These animals were crossed with tamoxifen-inducible Cre
(R26CreER) that is expressed in every cell. Therefore, any cell exposed to
tamoxifen would express Cre, thereby inducing mT excision and mG expression.
For example, when tamoxifen is injected intraperitoneally, every cell in the body
expresses mG, as demonstrated in Chapter V. It was proposed that i.v. injection
of PLGA nanoparticles would be sufficient to target hepatic macrophages. While
mG was robustly induced in the liver upon examination of green fluorescence in
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frozen tissues, it was observed that mG was also induced in the lung, indicating
that tamoxifen-loaded PLGA nanoparticles must have also targeted the lung.
After i.v. (tail vein) administration of a pharmacologic agent, the first
capillary bed that agent contacts is the lung. This property may explain why
green fluorescence was observed in both the liver and lung. As such, a more
liver-specific delivery method was required. Blood from the spleen empties
directly into the hepatic portal vein, thereby making intrasplenic injection an,
essentially, direct route of administration of pharmacologic agents to the liver.
Furthermore, the majority of PLGA nanoparticles, when injected intrasplenically,
have been shown to accumulate in Kupffer cells (89). It was therefore proposed
that intrasplenic administration of PLGA nanoparticles would induce Cremediated excision in the liver, while avoiding off-target organs like the lung.
As such, to address the second goal of this study, tamoxifen-loaded PLGA
nanoparticles were injected intrasplenically in R26CreER+/mTmG+ mice.
Interestingly, the experiments in Chapter V demonstrate that this method induces
dose-dependent expression of Egfp in the liver, but did not induce expression in
the lung, kidney, or spleen when compared to injection of vehicle control. At all
doses of nanoparticles injected, both hepatocytes and non-parenchymal cells
appeared to express mG. Taken together, the data from Chapter V indicate that
liver-specific (intrasplenic) delivery of tamoxifen-loaded PLGA nanoparticles may
be sufficient to selectively induce Cre-mediated excision in hepatic macrophages
while avoiding macrophage populations in other tissues, including the lung.
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Text Box 6.3

Take-home points

C.



Chapter V identified a drug delivery vehicle (tamoxifen encapsulated
in PLGA nanoparticles) and a suitable reporter system (a dualfluorescence reporter construct regulated by tamoxifen-inducible Cre
to develop an in-vivo model to investigate the liver-lung axis.



Intrasplenic, but not intravenous, administration of nanoparticles
selectively induced Cre-mediated excision of the reporter construct in
the liver, and not in the lung.

Significance of new findings
As discussed in Chapter I, alcohol abuse is the number one risk factor for

developing ARDS in the setting of sepsis. However, the mechanisms by which
alcohol sensitizes the lung to development of ALI and ARDS are poorly
understood. One of the primary aims of this dissertation was to utilize knowledge
of established mechanisms in alcohol-induced liver injury to unmask novel
mechanisms of alcohol-enhanced lung injury. The experiments in Chapter III
identify a novel role for the fibrinolytic inhibitor, PAI-1, and by extension, fibrin
accumulation and integrin β3- mediated platelet aggregation. The results from
this study suggest that alcohol pre-exposure enhances PAI-1 induction after LPS
administration, thereby promoting accumulation of fibrin in the lung tissue, which
acts as the ligand for platelet aggregation via platelet integrin αIIBβ3. This study
revealed several potential druggable targets which could be explored for
prevention of the development of ARDS in at-risk individuals. For example, anti-
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coagulants are already being actively clinically explored as treatment options for
sepsis-induced ARDS (151). Additionally, platelet aggregation inhibitors are FDA
approved and readily clinically available. The studies presented in Chapter III,
therefore, are just one example of how understanding parallel mechanisms of
liver and lung injury may provide new treatment options for at-risk patients.
Murine models are useful tools to investigate mechanisms by which
alcohol pre-exposure promotes injury and inflammation in target organs,
including the liver and the lung. However, many animal models employed are
limited in their ability to recapitulate risky human drinking patterns and the human
pathologies that are associated with them. The recently developed “acute-onchronic” or “chronic + binge” mouse model of alcohol exposure more accurately
reproduces risky human drinking behavior, in which episodes of binge drinking
are coupled with alcohol abuse. Liver pathology in this model of alcohol exposure
is well characterized (152). This pattern of ethanol exposure in mice produces a
phenotype more similar to human alcoholic steatohepatitis, including hepatic fat
accumulation, neutrophil infiltration, and necrosis. Novel findings in Chapter IV
show that chronic + binge alcohol exposure also promotes inflammation and
airway hyper-responsiveness in the lung. This work has characterized the effects
of a new model of ethanol exposure in mice, unmasking lung pathologies that are
not seen with different models of ethanol administration. Importantly, this study
is the first to demonstrate that ethanol exposure alone, absent any exogenous
inflammatory insult (e.g., LPS), is sufficient to induce inflammation in the lung.
Additionally, population studies have indicated that in some individuals, alcohol
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consumption can trigger asthma attacks. However, these episodes have
traditionally been linked to impurities in alcoholic beverages and/or acetaldehyde
detoxification insufficiencies. The experiments in Chapter IV indicate that ethanol
alone may contribute to mild airway hyperresponsiveness. Taken together, these
results indicate that this model may be used in the future to investigate how
ethanol exposure may drive the development of a pro-inflammatory milieu in the
lung and airways, thereby promoting injury. Once again, these studies represent
another example of how understanding alcohol-induced toxicity in one organ,
such as the liver, may provide novel insight into a second target organ, like the
lung.
Finally, the third Aim of this dissertation sought to develop a tool that could
be used to empirically assess the role of hepatic, or more specifically, Kupffercell derived cytokines in the development of alcohol-enhanced acute lung injury.
The experiments in Chapter V demonstrate that when tamoxifen-loaded PLGA
nanoparticles are delivered directly to the liver of animals expressing tamoxifeninducible Cre recombinase, Cre-mediated excision occurs exclusively in the liver,
with recombination occurring in both hepatocytes and non-parenchymal cells,
including Kupffer cells. These results are significant for several reasons. First,
these experiments have developed a tool to discern the role of hepatic-derived
cytokines in alcohol-enhanced acute lung injury. To date, no Kupffer cell-specific
promotor has been identified that exclusively targets resident hepatic
macrophages while avoiding macrophages in other tissues, including the lung. In
the system developed in Chapter V, the role of any gene that can be flox-flanked
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may be assessed. For example, to determine the role of hepatic-derived TNFα in
alcohol-enhanced ALI, the commercially-available, flox-flanked TNFα converting
enzyme (TACEflox ) mouse could be employed. Selective deletion of this enzyme
could, in theory, prevent the release of TNFα from the liver into systemic
circulation while not affecting local, paracrine effects of TNFα in the liver.
Second, while communication between the liver and lung may be of most interest
for the current study, the role of hepatic-derived cytokines in alcohol-induced
toxicity is of great interest in other organs as well. For example, systemic TNFα is
established to play a role in alcohol-induced brain inflammation (153). The
system described in Chapter V would be useful for determining the origin of this
systemic cytokine. Third, the applications of this system are not limited to the
context of alcohol-induced organ toxicity. For example, hepatic macrophages
have been widely implicated in multiple organ failure in acute pancreatitis (147).
The system described in Chapter V could be utilized to investigate the specific
role of any flox-flanked gene in hepatic macrophages in this disease. Finally, the
development of this tool has implications beyond the scope of basic research.
Clinically, identifying the role of hepatic-derived cytokines in alcohol-induced
toxicity in the lung, as well as other organs, provides novel insight for the
treatment of these conditions. For example, these data provide support for
identifying underlying liver disease as a screening and/or treatment goal in
patients at risk for developing ARDS, as well as other systemic diseases.
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D.

Strengths and weaknesses
1. Strengths
There are several strengths of the work presented in this dissertation.

First, this work uses relevant whole animal models to address the Aims
presented here. The effects of alcohol use are complex phenomena which are
not limited to a single organ or cell type, directly supporting the necessity of the
work presented in this dissertation which investigates parallel mechanisms of
injury in the liver and lung, as well as the potential interdependence of these two
organs, during alcohol exposure. The questions explored here could likely not be
sufficiently addressed by the use of other model systems (e.g., cultured cells). In
particular, this study explores the effects of a new, relevant mouse model of
ethanol exposure in the lung. Chronic + binge ethanol exposure has been
characterized as, perhaps, a more clinically-relevant mouse model of ethanol
exposure. Blood alcohol levels achieved in this model, as well as the liver
pathology it produces, are similar to that of individuals at risk of developing
alcohol-induced disease. For example, increased risk of ARDS only occurs in
patients consuming more than three drinks per day (127). For the first time, the
work in this dissertation explores the effects of chronic + binge alcohol exposure
on the lung, and produced the novel finding that, under these conditions, ethanol
alone is sufficient to cause pulmonary inflammation and alter lung mechanics.
In addition to exploring alternative alcohol exposure models to investigate
the effects of ethanol on the lung, this dissertation also developed a new tool to
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gain novel insight in the liver-lung axis of disease. The wide range of applications
for this new tool is an obvious strength of the work presented in this dissertation.
The use of a tamoxifen-inducible ubiquitous promotor allows for targeted excision
of any gene of interest that is flox-flanked. As mentioned previously, targeted
deletion of TNFα converting enzyme (TACE) from the liver, specifically hepatic
macrophages, would prevent the release of TNFα from the liver into systemic
circulation and, if the hypothesis is correct, protect against alcohol-enhanced
acute lung injury. However, even if this hypothesis is insufficient, the system
developed here would allow for selective deletion of other genes, and depending
on the nanoparticle delivery method, selective deletion of genes from other
macrophage populations.
Finally, this dissertation has identified a new mechanism of alcoholenhanced ALI. Building on knowledge of the role of the protease inhibitor, PAI-1
in alcohol-induced liver injury, this dissertation sought to explore the idea that
similar mechanisms involving transitional ECM remodeling may be involved in
alcohol-enhanced lung injury. Using an established model of experimental
endotoxemia with ethanol pre-exposure, the experiments in Chapter III
demonstrated a novel role for PAI-1 and subsequent fibrin accumulation and
platelet aggregation. While platelets have been implicated in other forms of lung
injury (103), the involvement of platelets in alcohol-enhanced ALI has not been
explored. This dissertation has identified novel, druggable targets to prevent the
progression of ARDS, such as PAI-1, fibrin, and platelet aggregation (potentially
via integrin αIIBβ3). In fact, treatment options targeting dysregulation of the
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coagulation cascade (e.g., nebulized heparin) are already being investigated as
promising treatment options in patients with ARDS (154)
.
2. Weaknesses
Although the animal models employed in this dissertation are a key
strength of this body of work, they also add a source of complexity. First,
because a conditional (i.e., flox-flanked) PAI-1 knockout mouse is not currently
commercially available, whole-body knockouts were used. This approach,
unfortunately, does not allow for the assessment of the effect of the deletion in a
tissue of interest, in this case, lung, or a specific cell type. It is possible,
therefore, that effects of PAI-1 deletion observed in this model may be due to the
modulation of PAI-1’s pro-inflammatory effects in other tissues, such as the liver.
In addition to specific limitations of the animal models used, there is
always an element of uncertainty when using animal models to attempt to
recapitulate human disease. Although in-vivo research is certainly preferred to
simpler models, such as cultured cells, to both the effects of chronic alcohol
exposure on a specific tissue (the lung) as well as organ-organ crosstalk during
chronic alcohol exposure, no animal model can completely recapitulate the
human condition. Indeed, there is currently no rodent model that exactly
represents the pattern of progression of alcoholic liver disease or alcoholenhanced susceptibility to ALI, or all of the clinical sequela associated with these
disease states. Although increased PAI-1 levels has been associated with
increased mortality in ARDS patients (52), there are currently no clinical studies
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investigating if ARDS patients with a history of alcohol abuse have elevated
plasma or BALF levels of PAI-1 compared to patients who do not have an alcohol
use disorder. Additionally, the “chronic + binge” mouse model of alcohol
exposure employed in this dissertation more accurately reproduces
characteristics of human alcoholic liver disease, including hepatic neutrophil
infiltration and inflammation. However, the effects of this alcohol exposure
pattern have not been examined clinically in the lung. Indeed, the pulmonary
inflammation and functional effects presented in mice in this dissertation were
relatively mild. As such, if this low-grade inflammation were to occur in the
human population, it may remain clinically silent in routine examination (i.e., if no
obvious lung injury has occurred). Therefore, a direct correlation of the findings
in Chapter IV to a human population is difficult to determine.
This dissertation also has limitations in terms of the experimental
approaches that were employed. For example, the experiments in Chapter III use
genetic modification (PAI-1 knockout and Integrin β3 knockout) to investigate the
role of PAI-1, fibrin accumulation, and platelet aggregation in alcohol-enhanced
ALI. Based on the results of this study, it was concluded that ethanol-enhanced
PAI-1 induction in the lung may contribute to exacerbated fibrin deposition and
platelet aggregation, and these aggregated platelets may contribute to lung injury
by driving chemokine expression and/or inflammatory damage in the tissue.
However, this study did not directly test the role of platelets themselves. For
example, platelet depletion using a depleting antibody, or administration of
platelet activation inhibitors, such as clopidogrel, would more directly address the
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role of platelets in this proposed mechanistic pathway. Furthermore, the
approach utilized in Chapter V relied on tamoxifen-inducible Cre-recombinase
driven by a ubiquitous promotor paired with liver-specific delivery of tamoxifen to
selectively modify the genetics of Kupffer cells. However, although it was
histologically observed that Cre-mediated mG expression was robustly induced
in Kupffer cells, mG expression was also noted in hepatocytes and possibly other
non-parenchymal cells. The current approach outlined in Chapter V will therefore,
likely not be sufficient to specifically target Kupffer cells while avoiding other
hepatic cell types.
Finally, the primary goal of the experiments in Chapter V was to develop
an animal model that may be used to interrogate the role of hepatic-derived
cytokines in alcohol-enhanced ALI. This model, therefore, does not address the
possibility that communication between the liver and lung may be bi-directional.
Indeed, in experimental studies of ventilator-induced ALI, data suggests
mediators released from the lung may damage tissues in other organs, including
the liver (149, 150). One advantage of the system developed in Chapter V is that
the dose and route of administration of nanoparticles could be altered to target
macrophage populations in other tissues. For example, direct administration of
nanoparticles to the lung (e.g., intratracheal instillation or oropharyngeal
aspiration) would likely selectively target alveolar macrophages, while avoiding
hepatic macrophages. Additionally, the current system will only address the role
of inflammatory mediators released from the cells that are residing in the liver at
the time of intrasplenic nanoparticle injection. Recent studies have suggested
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chronic alcohol administration causes infiltration of monocyte-derived
macrophages into the liver (155). While the exact role of these infiltrating
inflammatory cells, compared to that of the macrophages residing in the liver, is
still widely debated, it is proposed that at least a subpopulation of the recruited
macrophages promote inflammatory tissue damage (156). Although the system
proposed in Chapter V may be limited by its inability to target macrophages that
are recruited after the time of injection, this limitation may also be a strength
because it allows for separation of the effects of resident versus recruited
macrophages on systemic release of inflammatory mediators. However, it is
possible that blocking release of inflammatory mediators into circulation may
attenuate the recruitment of inflammatory cells into the liver. Future studies
should consider the limitations presented here to further investigate these
important research questions.
Summary Table 6.1

Strengths
 Relevant animal model of chronic
+binge alcohol exposure unmasks
alcohol-induced pathology in lung

Limitations
 Pathologies identified in animal
models used here remain
uninvestigated in human patients.

 Novel approach to investigate
liver-lung interactions has a wide
range of applications, inside and
outside the context of this
dissertation

 Liver-specific, transgenic system
targets multiple hepatic cell
types and does not address
potential for bi-directional
communication

 Clinically relevant, new,
druggable targets in alcoholenhanced ALI for at-risk patients
identified.
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Exact role of platelets in this novel
mechanism of ALI requires
further investigation.

E.

Future Directions
While the experiments described in this dissertation answered specific

gaps in the field’s knowledge of the alcoholic lung phenotype and the liver-lung
axis of disease, it has also created new questions to be addressed in future
studies. Some of these questions are addressed below.

1. What is the role of platelet activation in alcohol-enhanced ALI?

The experiments performed in Chapter III identified fibrin-mediated platelet
aggregation as a mechanism by which alcohol enhances endotoxemia-induced
ALI. Deletion of the β subunit of integrin αIIBβ3, an integrin involved in platelet
adherence to fibrin, significantly blocked alcohol-enhanced chemokine
expression and PAI-1 expression. A logical next step for future experiments
would be to directly test the role of platelets and platelet activation in the
development of the alcoholic lung phenotype. This question could be addressed
by various approaches. First, to more broadly test the hypothesis that platelet
accumulation promotes chemokine expression in the lung, platelets could be
depleted from the whole animal by injection of an anti-CD41 monoclonal antibody
(157). Next, platelet inhibitors could be used to more specifically interrogate
various platelet functions. Integrin αIIBβ3 inhibitors, such as abciximab, prevents
adhesion of platelets (158). Clopidegrel is an antagonist of the platelet ADP
receptor, P2Y12; administration of this drug could investigate the specific role of
activated platelets. More “platelet-specific” genetic approaches could also be
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utilized (159). For example, mice lacking protease-activated receptor-4 (PAR-4),
the platelet receptor for thrombin, is also an available option to study platelet
activation in alcohol-enhanced ALI. Indeed, thrombin, a potent activator of
platelets, was elevated in the plasma of animals exposed to ethanol and LPS. It
is proposed that blocking platelet activation would mitigate alcohol-enhanced
cytokine and chemokine expression, and ultimately, inflammatory injury.
Additionally, the effect of the pattern and dose of alcohol exposure (i.e., chronic
alcohol versus chronic + binge alcohol) would be an interesting question to
explore. Further investigating the contribution of platelets to alcohol-enhanced
ALI would be an interesting future direction for this study.
Summary Table 6.2

Platelet activation in ALI?
Rationale

Blocking platelet aggregation significantly attenuated
alcohol-enhanced chemokine expression in the lung.

Approach

Platelets may be depleted entirely using monoclonal
antibodies, or drugs and/or genetic modification can be
used to target specific activation pathways.

Expected Results

Blocking platelet activation will mitigate alcoholenhanced ALI.

2. To what extent is the mechanism identified in Chapter III involved in
alcohol-induced liver injury?
A major goal of this dissertation was to utilize established mechanisms of
alcohol-induced liver injury to explore new questions about alcohol-enhanced
ALI. The Arteel group found that PAI-1 induction and subsequent fibrin
accumulation were critical in the development of liver injury and inflammation in
the setting of chronic alcohol exposure (47), as well as acute alcohol-enhanced
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LPS-induced liver injury (38). It was therefore proposed that similar mechanisms
may be involved in alcohol-enhanced ALI. During this investigation, a new
mechanism of inflammation, potentially mediated by platelets, was uncovered.
An interesting target for further investigation would be to determine if this is a
parallel mechanism of injury in the liver. One study demonstrated that platelets
accumulate in the periportal microcirculation after acute ethanol administration in
mice (160). Paradoxically, thrombocytopenia, or low platelet levels, is associated
with chronic liver diseases, including alcoholic cirrhosis. It is proposed by others,
however, that thrombocytopenia in end-stage liver disease may be a product of
decompensation and not necessarily involved in pathogenesis at this stage of
disease (161). The involvement of platelets in the inflammatory phase of
alcoholic liver disease is unknown, and would therefore be an interesting
question for future study. To study this effect, the model of chronic alcohol
exposure with experimental endotoxemia employed in this dissertation could be
utilized, and platelet accumulation could be detected in the liver
immunohistochemically, as described in the lung in Chapter III. If platelets are
found to accumulate in the liver, similar approaches as described in the previous
section could be employed to determine if platelet activation contributes to
alcohol-induced liver injury. Based on the findings of this dissertation, it is
expected that platelet aggregation may occur in the liver in this disease model,
and that blocking this aggregation may attenuate alcohol-induced liver injury.
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Summary Table 6.3

Role of platelets in alcohol-induced liver injury?
Rationale

Blocking platelet aggregation significantly attenuated
alcohol-enhanced chemokine expression in the lung.

Approach

Platelets may be depleted entirely using monoclonal
antibodies, or drugs and/or genetic modification can be
used to target specific activation pathways.

Expected Results

Blocking platelet activation may attenuate alcohol
induced injury or inflammation.

3. What is the mechanism by which chronic + binge alcohol exposure
causes airway hyperresponsiveness?
Population studies have indicated that alcohol consumption may trigger
asthma attacks in certain individuals, including those with a genetic
polymorphism that prevents them from efficiently detoxifying acetaldehyde (127).
The effects of alcohol-induced damage, separate from alcohol intoxication itself,
on lung mechanics has not been extensively characterized. The experiments
outlined in Chapter IV demonstrate that chronic + binge alcohol exposure causes
airway hyperresponsiveness, as indicated by exacerbated resistance, Newtonian
resistance and respiratory resistance in response to inhaled methacholine. These
measurements were performed 24 hours after ethanol binge, and animals had
been fasted from ethanol. Therefore, it is unlikely that any effects on lung
mechanics seen in this study were due to alcohol intoxication or toxic alcohol
metabolites, such as acetaldehyde. Potential alternative mechanisms of airway
hyperresponsiveness would, therefore, be of interest to explore in future studies.
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Airway responsiveness to methacholine can be altered by a variety of
factors. First, interruption of the bronchial epithelium may exacerbate airway
resistance in response to methacholine by allowing the drug to more freely
access the underlying smooth muscle (162). The bronchial epithelium is
protected by layers of phospholipids, or surfactants. In one study, guinea pigs
exposed to chronic ethanol had significantly reduced surfactant levels in BALF
compared to control animals (163). Surfactant levels could be measured in
animals exposed to chronic + binge ethanol. If found to be reduced, an
intervention study could be performed to attempt to restore surfactant proteins
using a number of experimental approaches, including administration of
exogenous surfactant (164). If surfactant loss is involved in this phenomenon,
restoring surfactant may mitigate alcohol-induced airway hyperresponsiveness.
A second potential mechanism of exacerbated airway resistance is the
induction of oxidative stress (165). Indeed, oxidative stress is hypothesized to be
a key player in the alcoholic lung phenotype (4). Indices of oxidative stress, such
as glutathione depletion, could be measured in animals exposed to chronic +
binge ethanol. If elevated, antioxidants, such as N-acetyl cysteine, could be
administered to attempt to attenuate alcohol-induced airway
hyperresponsiveness (166).
Pulmonary inflammation can also promote airway hyperresponsiveness
(162). For example, the experiments in Chapter IV demonstrated that chronic +
binge alcohol exposure promotes neutrophil recruitment to the lung tissue and
airways. Neutrophils release reactive oxygen species, which may therefore be
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one potential mechanism of airway hyperresponsiveness seen in this model, as
previously discussed. Additionally, a study measuring cytokine and chemokine
levels in BALF of patients with alcohol use disorders found that regulated on
activation, normal T-cell expressed and secreted (RANTES/CCL5) levels
positively correlated with the severity of the alcohol use disorder (167, 168). The
role of this chemokine has been widely characterized in airway
hyperresponsiveness in asthma and allergic airway inflammation (169). One
potential future study could investigate levels of this chemokine in the BALF of
animals exposed to chronic + binge alcohol. If found to be elevated, the role of
this chemokine in alcohol-induced airway hyperresponsiveness could be
investigated in a commercially-available knockout mouse.
Finally, there is evidence suggesting that dyfunction of the
parasympathetic neurons innervating the airway may play a role in airway
hyperresponsiveness, but the exact mechanism has not been characterized
(170, 171). It is therefore possible that chronic + binge alcohol exposure may
somehow alter the innervation of the airway, thereby promoting
hyperresponsiveness. This hypothesis could be investigated via approaches that
block innervation, such as vagotomy. Taken together, these mechanisms,
including epithelial barrier dysfunction, oxidative stress, inflammation, and
innervation, are all plausible targets for future investigation. Furthermore, it would
be of interest to determine if other patterns of alcohol exposure, such as acute or
chronic alcohol exposure, also promote airway hyperresponsiveness, or if this
phenotype is unique to chronic + binge alcohol exposure.
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Summary Table 6.4

Mechanism of airway hyperresponsiveness?

Rationale

Approach

Expected Results

Chronic + binge ethanol caused increased airway
resistance in response to inhaled methacholine. Several
factors known to contribute to airway
hyperresponsiveness, including surfactant loss, oxidative
stress, inflammation, and innervation, have previously
been associated with alcohol exposure.
Exogenous surfactant administration, antioxidant
administration, genetic deletion of specific inflammatory
cytokines, or vagotomy may be used to investigate these
questions.
An intervention to target one of these mechanisms may
block alcohol-induced airway hyperresponsiveness.

4. Does hepatic-derived TNFα contribute to the alcoholic lung
phenotype?
The experiments described in Chapter V developed a new tool for
targeted transduction of cells in the liver that avoided the lung. While the
implications of this work are far-reaching, the most relevant to this dissertation is
that this system could be used to determine the role of hepatic-derived cytokines
in alcohol enhanced ALI. TNFα-converting enzyme (TACE) is an enzyme
required for cleavage and systemic release of TNFα into the blood. Previous
research from the Arteel group has suggested that extra-thoracic TNFα, at least
in part, drives alcohol-enhanced inflammation in endotoxemia-induced ALI. The
system developed in Chapter V could be easily used to selectively delete TACE
from the liver in mice expressing tamoxifen-inducible Cre and flox-flanked TACE.
The use of this system would target TACE deficiency to Kupffer cells and
hyepatocytes and, if the overall hypothesis is correct, block TNFα signaling in the
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lung. In fact, these are currently being generated, and preliminary studies are
being performed.
Summary Table 6.5

Role of hepatic TNFα in alcohol-enhanced ALI?
Rationale

Previous studies indicate extra-thoracic TNFα may
contribute to alcohol-enhanced ALI.

Approach

Using the liver-specific transduction method developed in
Chapter V, TACE could be selectively deleted from
hepatocytes and Kupffer cells.

Expected Results

Liver-specific deletion of TACE would prevent TNFα from
being released into circulation from the liver, preventing
TNFα-responsive signaling in the lung.

F.

Summary and conclusions
The overall goal of the work described here builds on the overarching

hypothesis that the liver and lung share parallel mechanisms of alcohol-induced
toxicity, and that liver injury may contribute, at least in part, to the development of
the “alcoholic lung phenotype.” The experiments in Chapter III describe a new
potential mechanism of alcohol-enhanced ALI driven by exacerbated fibrin
accumulation and platelet aggregation, identifying platelets as a target for
investigation of future study in both the liver and lung. Chapter IV characterizes
the effects of a perhaps more relevant ethanol exposure pattern in the lung,
building on findings that acute (binge) alcohol administration following chronic
alcohol exposure causes exacerbated liver injury and inflammation. Future
studies will seek to identify the mechanism by which chronic + binge alcohol
causes airway hyperresponsiveness. Finally, Chapter V describes the
development of a novel tool using liver-targeted delivery of tamoxifen-loaded
nanoparticles to selectively delete a gene of interest from hepatic macrophages
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that does not also target the lung. The implications for this system are farreaching, and importantly, can be used to selectively delete inflammatory factors
(e.g., TACE) from the liver to determine if mediators (TNFα) of hepatic origin
drive injury in the lung. Taken together, the data presented in this dissertation
shed new light on mechanisms by which alcohol promotes injury in the lung, as
well as developed a tool to examine the potential extra-thoracic origins of this
condition.
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ABBREVIATIONS

AH

Alcoholic hepatitis

ALD

alcoholic liver disease

ALI

Acute lung injury

ALT

Alanine aminotransferase

ANOVA

Analysis of variance

ARDS

Acute respiratory distress syndrome

AST

Aspartate aminotransferase

AUD

Alcohol use disorder

BAC

Blood alcohol content

BAL

Bronchoalveolar lavage

BALF

Bronchoalveolar lavage fluid

C

Compliance

CAE

Chloroacetate esterase

CCL5

C-C chemokine ligand-1

CD41

Cluster of differentiation-41

CD68

Cluster of differentiation-68

Cre

Cyclization recombinase

CXCL1

C-X-C chemokine ligand-1

CXCL15

C-X-C chemokine ligand-15

CXCL2

C-X-C chemokine ligand-2
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DALY

Disability-adjusted life year

DCM

Dichloromethane

ECM

Extracellular matrix

EGFP

Enhanced green fluorescent protein

ELISA

Enzyme-linked immunosorbent assay

EtOH

Ethanol

G

Tissue damping

H

Tissue elastance

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

HCV

Hepatitis C virus

ICAM-1

Intracellular adhesion molecule-1

IL-1β

Interleukin-1 beta

IL-22

Interleukin-22

IL-23

Interleukin-23

IL-6

Interleukin-6

KC

Keratinocyte chemotractant

Loxp

Locus of X(cross)-over in P1

LPS

Lipopolysaccharide

MCP-1

Monocyte chemotactic protein-1

mG

Membrane-targeted enhanced green fluorescent protein

a

Macrophage inflammatory protein-2
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MMP

matrix metalloprotease

mT

Membrane-targeted tandem-dimer Tomato

NIAAA

National Institute on Alcohol Abuse and Alcoholism

NP

Nanoparticle

PAI-1

Plasminogen activator inhibitor-1

PAR

Protease-activated receptor

PBS

Phosphate-buffered saline

PECAM

Platelet-endothelial cell adhesion molecule

PFA

Paraformaldehyde

PLGA

Poly(lactic-co-glycolic acid)

PMN

Polymorphonuclear leukocyte

qRT-PCR Quantitative reverse transcription polymerase chain reaction
RANTES Regulated on activation, normal T-cell expressed and secreted
RGD

arginine-glycine-aspartic acid domain

Rn

Newtonian resistance

Rrs

Resistance

SEM

Standard error of the mean

SIRS

Systemic inflammatory response syndrome

TACE

TNFα-converting enzyme

TAT

Thrombin anti-thrombin

TNFα

Tumor necrosis factor-alpha

tPA

Tissue-type plasminogen activator
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uPA

Urokinase-type plasminogen activator

VCAM-1

Vascular cell adhesion molecule-1

WT

Wildtype
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